Document:

Exhibit

2019 AFI RSU |CASH  (NON-US/CHINA)

Exhibit 10.9

	
		
	2019 Long-Term Time-Based Restricted Stock Unit Grant

	ARMSTRONG FLOORING, INC.
2500 Columbia Ave., P.O. Box 3025
Lancaster, PA 17604
717.672.9611
 

	
		
	[Participant Name]

	

I am pleased to inform you that the Company’s Management Development and Compensation Committee granted you the following: 

	
		
	Date of Grant:
	March 7, 2019

	Time-Based Restricted Stock Units:
	[Number of Stock Untis Granted]

This grant is subject to the terms of the 2016 Long-Term Incentive Plan and the award agreement.  The award agreement consists of this grant letter and the Terms and Conditions attached as Exhibit A.

Vesting - The Restricted Stock Units will vest in accordance with the following schedule, if you remain employed by the Employer through the applicable vesting date, except as described below.  The Restricted Stock Units will be paid in cash. 

	
				
	 
	Vesting Date
	Time-Based Units Vesting
	 

	 
	One year from Date of Grant
	33.33%
	 

	 
	Two years from Date of Grant
	33.33%
	 

	 
	Three years from Date of Grant
	33.34%
	 

Employment Events
The following chart is a summary of the provisions which apply to this award in connection with your termination of employment.  The following is only a summary, and in the event of termination of employment, the award will be governed by the Terms and Conditions.

2019 AFI RSU |CASH  (NON-US/CHINA)

Exhibit 10.9

	
			
	 
	Event
	Provisions

	n
	Voluntary Resignation
	Forfeit all unvested Restricted Stock Units and accrued dividends

	n
	Termination for Cause
	Forfeit all unpaid (vested or unvested) Restricted Stock Units and accrued dividends

	n
	"55 / 5" Rule Termination                                                              (55 years of age or older with 5 years of service)
	If termination occurs after 10 months following the Date of Grant, Restricted Stock Units and accrued dividends vest pro-rata based on the period of employment; otherwise unvested Restricted Stock Units and accrued dividends are forfeited

	n
	Involuntary Termination

	n
	Death
	Restricted Stock Units and accrued dividends vest pro-rata based on the period of employment

	n
	Long-Term Disability

	n
	Involuntary Termination upon or within two years following a Change of Control
	Restricted Stock Units and accrued dividends vest in full upon termination of employment

	 

Each Restricted Stock Unit granted is credited to an account maintained for you.  You have no ownership or voting rights relative to these Restricted Stock Units.  If the Company makes cash dividend payments before the Restricted Stock Units are vested, the value of the dividends will accrue in a non-interest bearing bookkeeping account.  You will receive a cash payment for the accrued dividend equivalents based on vesting and payment of the Restricted Stock Units.  

In the event of any inconsistency between the foregoing summary and the Terms and Conditions or the 2016 Long-Term Incentive Plan, the Terms and Conditions or the 2016 Long-Term Incentive Plan, as applicable, will govern.  Capitalized terms used but not defined in this grant letter will have the meanings set forth in the 2016 Long-Term Incentive Plan or the Terms and Conditions, as applicable.

Please note that the Terms and Conditions contain restrictive covenant language pertaining to confidentiality, non-competition and non-solicitation.  You should read these sections carefully before deciding whether to accept the Restricted Stock Units.  If you decide not to accept the Restricted Stock Units, you will not be subject to the restrictive covenants set forth in the Terms and Conditions, but you will forfeit the Restricted Stock Units.  You will continue to be subject to any restrictive covenants set forth in the 2016 Long-Term Incentive Plan with respect to prior equity grants and any other agreements between you and the Company.  There will be no other consequences as a result of your decision not to accept the Restricted Stock Units.    

Please contact Robert Bell (717-672-7158) if you have questions.

Sincerely,

Donald R. Maier
President and Chief Executive Officer

2

2019 AFI RSU |CASH  (NON-US/CHINA)

Exhibit 10.9

EXHIBIT A

ARMSTRONG FLOORING, INC.
2016 LONG-TERM INCENTIVE PLAN
    
TIME-BASED RESTRICTED STOCK UNIT GRANT
TERMS AND CONDITIONS

1.Grant.  
(a)    Subject to the terms set forth below, Armstrong Flooring, Inc. (the “Company”) has granted to the designated employee (the “Grantee”) an award of time-based restricted stock units (the “Time-Based Units”) as specified in the 2019 Long-Term Time-Based Restricted Stock Unit Grant Letter to which these Grant Conditions relate (the “Grant Letter”).  The “Date of Grant” is March 7, 2019.  The Time-Based Units are Stock Units that relate to common stock of the Company (“Company Stock”) and entitle the Grantee to receive a cash bonus payment from the Grantee’s employer subject to the terms set forth below.    
(b)    The Time-Based Units shall be vested and payable in accordance with the schedule set forth below, if and to the extent the terms of the Grant Letter and these Grant Conditions are met.
(c)    These Terms and Conditions (the “Grant Conditions”) are part of the Grant Letter.  This grant is made under the Armstrong Flooring, Inc. 2016 Long-Term Incentive Plan (the “Plan”).  Any terms not defined herein shall have the meanings set forth in the Plan.  
2.    Vesting.  
(a)    Except as provided in Sections 3 and 4 below, the Time-Based Units shall vest on the following dates, if the Grantee continues to be employed by the Company or its subsidiaries or affiliates (collectively, the “Employer”) on the applicable dates below (each individually, a “Vesting Date”):
	
		
	Vesting Date
	Time-Based Units Vesting

	One year from Date of Grant
	33.33%

	Two years from Date of Grant
	33.33%

	Three years from Date of Grant (the “Third Vesting Date”)

	33.34%

(b)    The vesting of the Time-Based Units is cumulative, but shall not exceed 100% of the Time-Based Units.  If the foregoing schedule or the provisions of Section 3 would produce fractional units, the number of Time-Based Units vesting shall be rounded up to the nearest whole unit, but not in excess of 100% of the Time-Based Units.  
3.    Termination of Employment.  
(a)    Except as described below, if the Grantee ceases to be employed by the Employer for any reason prior to the Third Vesting Date, the unvested Time-Based Units shall be forfeited as of the termination date and shall cease to be outstanding.  
(b)    Subject to Section 4 below, if, prior to the Third Vesting Date, the Grantee ceases to be employed by the Employer (x) on account of death or Long-Term Disability (as defined below), or (y) after ten months following the Date of Grant, on account of “55 / 5” Rule Termination (as defined below) or Involuntary Termination (as defined below) (each, a “Qualifying Termination”), the Grantee shall vest in a pro-rated portion of the granted Time-Based 

3

2019 AFI RSU |CASH  (NON-US/CHINA)

Exhibit 10.9

Units in accordance with this Section 3(b), provided such vesting does not result in a violation of any age discrimination or other applicable law.  The pro-rated portion shall be determined by multiplying the number of Time-Based Units by a fraction, the numerator of which is the number of calendar months in the period starting with (i) the first calendar month following the month in which the Date of Grant occurs through (ii) the calendar month in which the Qualifying Termination date occurs, with such final calendar month counting as a full month, and the denominator of which is 36, and subtracting the Time-Based Units that had vested as of the Qualifying Termination date in accordance with Section
2.  The pro-rated Time-Based Units shall be paid within 60 days after the Grantee’s termination date, as described in Section 7.  The unvested Time-Based Units, if any, shall be forfeited as of the termination date and shall cease to be outstanding.
(c)    If the Grantee ceases to be employed by the Employer on account of Cause (as defined below), any unpaid Time-Based Units (vested or unvested) shall be forfeited as of the termination date and shall cease to be outstanding.
4.    Change in Control Involuntary Termination.  Subject to Section 14 of the Plan, and notwithstanding Section 3 above, if the Grantee has an Involuntary Termination upon or within two years after a Change in Control, and prior to the Third Vesting Date, the Grantee’s outstanding Time-Based Units shall become fully vested and shall be paid within 60 days after such Involuntary Termination, as described in Section 7. 
5.    Definitions.  For purposes of these Grant Conditions and the Grant Letter:
(a)    “‘55 / 5’ Rule Termination” shall mean the Grantee’s termination of employment other than for Cause after the Grantee has attained age 55 and has completed five years of service with the Employer.
(b)    “Cause” shall mean any of the following, as determined in the sole discretion of the Employer: (i) commission of a felony or a crime involving moral turpitude; (ii) fraud, dishonesty, misrepresentation, theft or misappropriation of funds with respect to the Employer; (iii) violation of the Employer’s Code of Conduct or employment policies, as in effect from time to time; (iv) breach of any written noncompetition, confidentiality or non-solicitation covenant of  the Grantee with respect to the Employer; or (v) gross negligence or misconduct in the performance of the Grantee’s duties with the Employer.
(c)    “Company Trade Secrets” shall have the meaning ascribed to the term on Attachment 1, the terms of which are incorporated herein.
(d)    “Confidential Information” shall have the meaning ascribed to the term on Attachment 1, the terms of which are incorporated herein.
(e)    “Injurious Conduct” shall have the meaning ascribed to the term on Attachment 1, the terms of which are incorporated herein. 
(f)    “Involuntary Termination” shall mean the Employer’s termination of the Grantee’s employment other than for Cause.   
(g)    “Long-Term Disability” shall mean the Grantee is receiving long-term disability benefits under the Employer’s long-term disability plan. 
6.    Restrictive Covenants; Forfeiture.
(a)    The Committee may determine that the Time-Based Units shall be forfeited if the Grantee engages in Injurious Conduct.

4

2019 AFI RSU |CASH  (NON-US/CHINA)

Exhibit 10.9

(b)    If the Committee determines that the Grantee has engaged in Injurious Conduct, the Committee may in its discretion require the Grantee to return to the Company any Company Stock or cash received in settlement of Time-Based Units.  
(c)    The Committee shall exercise the right of forfeiture and recoupment provided to the Company in this Section 6 within 180 days after the Company’s discovery of the Injurious Conduct activities giving rise to the Company’s right of forfeiture or recoupment.
(d)    The Grantee may make a request to the Committee in writing for a determination regarding whether any proposed business or activity would constitute Injurious Conduct.  Such request shall fully describe the proposed business or activity.  The Committee shall respond to the Grantee in writing and the Committee’s determination shall be limited to the specific business or activity so described.
(e)    By accepting the Time-Based Units, the Grantee acknowledges and agrees that all Company Trade Secrets and Confidential Information developed, created or maintained by the Grantee, alone or with others, during the Grantee’s employment or service with the Employer, shall remain at all times the sole property of the Company and its subsidiaries and affiliates.

 (f) This Agreement consists of a series of separate restrictive covenants, all of which shall survive and be enforceable in law and/or equity after the Grantee’s termination or cessation of the Grantee’s employment or service with the Employer.  The Grantee understands that in the event of a violation of any provision of this Section 6, the Company shall have the right to seek injunctive relief, in addition to any other existing rights provided in this Agreement or by operation of law, without the requirement of posting bond. The remedies provided in this Section 6 shall be in addition to any legal or equitable remedies existing at law or provided for in any other agreement between the Grantee and the Company or any of its subsidiaries or affiliates, and shall not be construed as a limitation upon, or as an alternative or in lieu of, any such remedies. If any provisions of this Section 6 and Attachment 1 shall be determined by a court of competent jurisdiction to be unenforceable in part by reason of it being too great a period of time or covering too great a geographical area, it shall be in full force and effect as to that period of time or geographical area determined to be reasonable by the court.
(g)    By accepting the Time-Based Units, the Grantee acknowledges that the Grantee has carefully read and considered the provisions of this Section 6 and Attachment 1 and agrees that the restrictions set forth herein are fair and reasonable, are supported by valid consideration, and are reasonably required to protect the legitimate business interests of the Company and its subsidiaries and affiliates.
(h)    In the event of a breach by the Grantee of any restrictive covenant set forth on Attachment 1, the running of the period of restriction shall automatically be tolled and suspended for the amount of time the breach continues, and shall automatically commence when the breach is remedied so that the Company and its subsidiaries and affiliates shall receive the benefit of the Grantee’s compliance with the terms and conditions of this Section 6.
7.    Payment.  When Time-Based Units vest, the Company shall cause the Grantee’s employer to make a cash payment to the Grantee, payable in local currency, equal to the Fair Market Value of the shares of Company Stock underlying the vested Time-Based Units (rounded up to the nearest whole share), subject to applicable withholding for Taxes (as defined below).  The Fair Market Value of the shares shall be determined as of the date immediately before the payment date.  Payment shall be made within 60 days after the applicable vesting date.
8.    Dividend Equivalents.  Dividend Equivalents shall accrue with respect to Time-Based Units and shall be payable subject to the same vesting terms and other conditions as the Time-Based Units to which they relate.  Dividend Equivalents shall be credited on the Time-Based Units when dividends are declared on shares of Company Stock from the Date of Grant until the payment date for the vested Time-Based Units.  The Company will keep records of Dividend Equivalents in a non-interest bearing bookkeeping account for the Grantee.  No interest will be credited to any such account.  Vested Dividend Equivalents shall be paid in cash at the same time and subject to the same terms as the underlying vested Time-Based Units.  If and to the extent that the underlying Time-Based Units are forfeited, all related Dividend Equivalents shall also be forfeited.  

5

2019 AFI RSU |CASH  (NON-US/CHINA)

Exhibit 10.9

9.    No Stockholder Rights.  No shares of Company Stock shall be issued to the Grantee with respect to the Time-Based Units, and the Grantee shall not be, nor have any of the rights or privileges of, a stockholder of the Company with respect to any Time-Based Units.     
10.    No Right to Continued Employment.  The grant of Time-Based Units shall not confer upon the Grantee any right to continued employment with the Employer or interfere with the right of the Employer to terminate the Grantee’s employment at any time. 
11.    Incorporation of Plan by Reference.  The Grant Letter and these Grant Conditions are made pursuant to the terms of the Plan, the terms of which are incorporated herein by reference, and shall in all respects be interpreted in accordance therewith. The decisions of the Management Development and Compensation Committee (the “Committee”) shall be conclusive upon any question arising hereunder. The Grantee’s receipt of the Time-Based Units constitutes the Grantee’s acknowledgment that all decisions and determinations of the Committee with respect to the Plan, the Grant Letter, these Grant Conditions, and the Time-Based Units shall be final and binding on the Grantee and any other person claiming an interest in the Time-Based Units.   
12.    Withholding Taxes.  
(a)    The Employer shall have the right, and the Grantee hereby authorizes the Employer, to deduct from all payments made hereunder and from other compensation an amount equal to the federal (including FICA), state, local and foreign taxes, social insurance, payroll tax, contributions, payment on account obligations or other amounts required by law to be collected, withheld or accounted for with respect to the Time-Based Units (the “Taxes”).  
(b)    Regardless of any action the Employer takes with respect to any such Taxes, the Grantee acknowledges that the ultimate liability for all such Taxes legally due by the Grantee is and remains the Grantee’s responsibility and may exceed the amount actually withheld by the Employer.  The Grantee further acknowledges that the Employer (i) makes no representations or undertakings regarding the treatment of any Taxes in connection with any aspect of the Time-Based Units, including the grant, vesting or settlement of the Time-Based Units and the receipt of any Dividend Equivalents; and (ii) does not commit to structure the terms of the grant or any aspect of the Time-Based Units to reduce or eliminate the Grantee’s liability for Taxes.  Further, if the Grantee has become subject to tax in more than one jurisdiction between the Date of Grant and the date of any relevant taxable event, the Grantee acknowledges that the Employer (or the Grantee’s former employer, as applicable) may be required to collect, withhold or account for Taxes in more than one jurisdiction.
13.    Company Policies.  All amounts payable under the Grant Letter and these Grant Conditions shall be subject to any applicable clawback or recoupment policies, share trading policies and other policies that may be implemented by the Company’s Board of Directors from time to time.   
14.    Assignment.      The Grant Letter and these Grant Conditions shall bind and inure to the benefit of the successors and assignees of the Company.  The Grantee may not sell, assign, transfer, pledge or otherwise dispose of the Time-Based Units, except to a successor grantee in the event of the Grantee’s death.
15.    Section 409A.  The Grant Letter and these Grant Conditions are intended to comply with section 409A of the Code or an exemption, consistent with Section 20(h) of the Plan.  In furtherance of the foregoing, if the Time-Based Units or related Dividend Equivalents constitute “nonqualified deferred compensation” within the meaning of section 409A of the Code, vested Time-Based Units and related Dividend Equivalents shall be settled on the earliest date that would be permitted under section 409A of the Code without incurring penalty or accelerated taxes thereunder.
16.    Successors.  The provisions of the Grant Letter and these Grant Conditions shall extend to any business that becomes a successor to the Company or its subsidiaries or affiliates on account of a merger, consolidation, sale of assets, spinoff or similar transaction with respect to any business of the Company or its subsidiaries or affiliates with which the Grantee is employed, and if this grant continues in effect after such corporate event, references to the “Company or its subsidiaries or affiliates” or the “Employer” in the Grant Letter and these Grant Conditions shall include the 

6

2019 AFI RSU |CASH  (NON-US/CHINA)

Exhibit 10.9

successor business and its affiliates, as appropriate.  In that event, the Company may make such modifications to the Grant Letter and these Grant Conditions as it deems appropriate to reflect the corporate event.
17.    Governing Law.  The validity, construction, interpretation and effect of the Grant Letter and these Grant Conditions shall be governed by, and determined in accordance with, the applicable laws of the State of Delaware, excluding any conflicts or choice of law rule or principle.  
18.    No Entitlement or Claims for Compensation.  In connection with the acceptance of the grant of the Time-Based Units under the Grant Letter and these Grant Conditions, the Grantee acknowledges the following:
(a)    the Plan is established voluntarily by the Company, the grant of the Time-Based Units under the Plan is made at the discretion of the Committee and the Plan may be modified, amended, suspended or terminated by the Company at any time;
(b)    the grant of the Time-Based Units under the Plan is voluntary and occasional and does not create any contractual or other right to receive future grants of Time-Based Units, or benefits in lieu of them, even if Time-Based Units have been granted repeatedly in the past;
(c)    all decisions with respect to future grants of Time-Based Units, if any, will be at the sole discretion of the Committee;
(d)    the Grantee is voluntarily participating in the Plan;
(e)    the Time-Based Units and any payments thereunder are extraordinary items that do not constitute compensation of any kind for services of any kind rendered to the Employer (including, as applicable, the Grantee’s employer) and which are outside the scope of the Grantee’s employment contract, if any;
(f)    the Time-Based Units and any payments thereunder are not to be considered part of the Grantee’s normal or expected compensation or salary for any purpose, including, but not limited to, calculating any severance, resignation, termination, payment in lieu of notice, redundancy, end of service payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar payments;
(g)    the Time-Based Units and any payments thereunder are not intended to replace any pension rights or compensation;
(h)    the grant of Time-Based Units and the Grantee’s participation in the Plan will not be interpreted to form an employment contract or relationship with the Employer;
(i)    the future value of the underlying shares of Company Stock is unknown and cannot be predicted with certainty.  The Grantee understands that the Company is not responsible for any foreign exchange fluctuation between the United States Dollar and the Grantee’s local currency that may affect the value of the Time-Based Units; and
(j)    the Grantee shall have no rights, claim or entitlement to compensation or damages as a result of the Grantee’s cessation of employment (for any reason whatsoever, whether or not in breach of contract or local labor law or the terms of the Grantee’s employment agreement, if any), insofar as these rights, claim or entitlement arise or may arise from the Grantee’s ceasing to have rights under or be entitled to receive payment under or ceasing to have the opportunity to participate in the Plan as a result of such cessation or loss or diminution in value of the Time-Based Units as a result of such cessation, and the Grantee irrevocably releases the Employer from any such rights, entitlement or claim that may arise.  If, notwithstanding the foregoing, any such right or claim is found by a court of competent jurisdiction to have arisen, then the Grantee shall be deemed to have irrevocably waived the Grantee’s entitlement to pursue such rights or claim.
19.    Data Privacy.  

7

2019 AFI RSU |CASH  (NON-US/CHINA)

Exhibit 10.9

(a)    The Grantee hereby explicitly, willingly and unambiguously consents to the collection, systematization, accumulation, storage, blocking, destruction, use, disclosure and transfer, in electronic or other form, of the Grantee’s personal data as described in these Grant Conditions by and among, as applicable, the Grantee’s employer, the Company or its subsidiaries or affiliates for the exclusive purpose of implementing, administering and managing the Grantee’s participation in the Plan.
(b)    The Grantee understands that the Grantee’s employer, the Company or its  subsidiaries or affiliates, as applicable, hold certain personal information and sensitive personal information about the Grantee regarding the Grantee’s employment, the nature and amount of the Grantee’s compensation and the fact and conditions of the Grantee’s participation in the Plan, including, but not limited to, the Grantee’s name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares of stock or directorships held in the Company or its subsidiaries or affiliates, and details of all awards in the Grantee’s favor, for the purpose of implementing, administering and managing the Plan (the “Data”).
(c)    The Grantee understands that the Data may be transferred, including any cross-border, transfer to the Company, its subsidiaries and affiliates and, to any third parties assisting in the implementation, administration and management of the Plan, that these recipients may be located in the Grantee’s country, or elsewhere, and that the recipient’s country may have different data privacy laws and protections than the Grantee’s country.  The Grantee understands that the Grantee may request a list with the names and addresses of any potential recipients of the Data by contacting the Grantee’s local human resources representative.  The Grantee authorizes the recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing the Grantee’s participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party.  The Grantee understands that the Data will be held only as long as is necessary to implement, administer and manage the Grantee’s participation in the Plan.  The Grantee understands that the Grantee may, at any time, view the Data, request additional information about the storage and processing of the Data, require any necessary amendments to the Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing the Grantee’s local human resources representative.  The Grantee understands, however, that refusing or withdrawing the Grantee’s consent may affect the Grantee’s ability to participate in the Plan.  For more information on the consequences of refusal to consent or withdrawal of consent, the Grantee understands that the Grantee may contact the Grantee’s local human resources representative.
*    *    *

8

2019 AFI RSU |CASH  (NON-US/CHINA)

Exhibit 10.9

Attachment 1

Definitions

For purposes of the Grant Letter and Grant Conditions, the following terms have the meanings ascribed to them on this Attachment 1:
(a)    “Company Trade Secrets” shall mean information, including a formula, pattern, compilation, program, device, method, technique or process, that: (i) derives independent economic value, actual or potential, from not being generally known to the public or to other persons or entities who can obtain economic value from its disclosure or use; and (ii) is the subject of efforts that are reasonable under the circumstances to maintain it secrecy.  Company Trade Secrets include, but are not limited to, the following: unique pricing methodologies and formulas for products and services of the Company or its subsidiaries or affiliates; unique marketing arrangements and strategies which the Company or its subsidiaries or affiliates use with their vendors and suppliers; and unique advertising arrangements and strategies that the Company or its subsidiaries or affiliates use to advertise their products and services.  For avoidance of doubt, Company Trade Secrets do not include any information that: (A) is already in the public domain or becomes available to the public through no breach by the Grantee of this Agreement; (B) was lawfully in the Grantee’s possession prior to disclosure to the Company or any of its subsidiaries or affiliates; (C) is lawfully disclosed to the Grantee by a third party without any obligations of confidentiality attaching to such disclosure; or (D) is developed by the Grantee entirely on the Grantee’s own time without equipment, supplies or facilities of the Company or its subsidiaries or affiliates and does not relate at the time of conception to business or actual or demonstrably anticipated research or development of the Company or its subsidiaries or affiliates.
(b)    “Confidential Information” shall mean information belonging to the Company or its subsidiaries or affiliates, whether reduced to writing or in a form from which such information can be obtained, translated or derived into reasonably usable form, that has been provided to the Grantee during his employment or service with the Employer and/or the Grantee has gained access to during the Grantee’s employment or service with the Employer and/or was developed by the Grantee in the course of the Grantee’s employment or service with the Employer, that is proprietary and confidential in nature. Confidential Information includes, but is not limited to, the following: information believed by the Company or any of its subsidiaries or affiliates to be a Company Trade Secret that ultimately does not qualify as such under applicable law but nonetheless was maintained by the Company or its subsidiaries or affiliates as confidential; information concerning the nature of the business and manner of operation of the Company and its subsidiaries and affiliates; the methods and systems used by the Company or its subsidiaries or affiliates in soliciting, selling and providing their services and/or products to their customers; financial and accounting information, such as cost, pricing and billing information, customer profiles, financial policies and procedures, and revenues and profit margins; sales and marketing information, such as sales strategies and programs; information concerning customers and prospective customers of the Company and its subsidiaries and affiliates; information concerning vendors and suppliers of the Company and its subsidiaries and affiliates; customer lists; prospective customer lists; customer buying habits and special needs; policies and procedures; personnel records; compensation paid to employees or other service providers of the Company or any of its subsidiaries or affiliates.  For avoidance of doubt, Confidential Information does not include any information that: (A) is already in the public domain or becomes available to the public through no breach by the Grantee of this Agreement; (B) was lawfully in the Grantee’s possession prior to disclosure to the Company or any of its subsidiaries or affiliates; (C) is lawfully disclosed to the Grantee by a third party without any obligations of confidentiality attaching to such disclosure; or (D) is developed by the Grantee entirely on the Grantee’s own time without equipment, supplies or facilities of the Company or its subsidiaries or affiliates and does not relate at the time of conception to business or actual or demonstrably anticipated research or development of the Company or its subsidiaries or affiliates.
(c)    “Injurious Conduct” shall mean the activities described in subsections (i), (ii), (iii), (iv) and (v) below and, for purposes of the Time-Based Units, shall replace the definition of “Injurious Conduct” set forth in Section 13 of the Plan. 

9

2019 AFI RSU |CASH  (NON-US/CHINA)

Exhibit 10.9

(i)    The Grantee’s employment or service with the Employer is terminated for willful, deliberate, or gross misconduct, as determined by the Committee, in its sole discretion;  
(ii)    During the Grantee’s employment or service with the Employer, the Grantee, directly for the Grantee or any third party, except on behalf of the Company or its subsidiaries or affiliates, becomes engaged in any business or activity which is directly in competition with any services or products sold by, or any business or activity engaged in by, the Company or any of its subsidiaries or affiliates; provided, however, that this provision shall not restrict the Grantee from owning or investing in publicly traded securities, so long as the Grantee’s aggregate holdings in such company do not exceed 2% of the outstanding equity of such company and such investment is passive;
(iii)    During the Grantee’s employment or service with the Employer and for a period of twelve (12)  months thereafter, the Grantee breaches any of the following:
(A)    The Grantee shall not, directly for the Grantee or any third party, except on behalf of the Company or its subsidiaries or affiliates, (I) (x) solicit business from any person who was a customer of the Company or any of its subsidiaries or affiliates during the period of the Grantee’s employment or service hereunder or who was within the six-month period prior to such solicitation, or (y) solicit potential customers who are or were identified through leads developed during the course of the Grantee’s employment or service with the Employer, in each case, with whom the Grantee was involved as part of the Grantee’s job responsibilities during the Grantee’s employment or service with the Employer, or regarding whom the Grantee learned Company Trade Secrets and/or Confidential Information during the Grantee’s employment or service with the Employer, or (II) otherwise divert or attempt to divert any existing business of the Company or any of its subsidiaries or affiliates; and
(B)    The Grantee shall not, directly for the Grantee or any third party, except on behalf of the Company or its subsidiaries or affiliates, (I) solicit, induce, recruit or cause another person in the employment of the Company or any of its subsidiaries or affiliates to terminate such employee’s employment, or (II) hire or retain any person who is, or within the six-month period prior to such hiring or retention was, an employee of the Company or any of its subsidiaries or affiliates; 
(iv)    During the Grantee’s employment or service with the Employer or thereafter, the Grantee uses, publishes or discloses any Company Trade Secrets and/or Confidential Information in any manner whatsoever, except as required in the conduct of business of the Company or any of its subsidiaries or affiliates or as authorized in writing by the Company or any of its subsidiaries or affiliates, as applicable.  By accepting the Time-Based Units, the Grantee acknowledges and agrees that (A) during the Grantee’s employment or service with the Employer, the Grantee has been or will be exposed to and/or provided with Company Trade Secrets and Confidential Information and (B) Company Trade Secrets are not generally known to the public or to competitors of the Company or its subsidiaries or affiliates, were developed or compiled at significant expense by the Company or its subsidiaries or affiliates over an extended period of time, are the subject of the reasonable efforts of the Company or its subsidiaries or affiliates to maintain their secrecy, and that the Company or its subsidiaries or affiliates derive significant independent economic value by keeping Company Trade Secrets a secret; or
(v)    During the Grantee’s employment or service with the Employer or thereafter, the Grantee breaches any other written confidentiality, non-solicitation or non-competition covenant with the Employer.

10Exhibit 10.1

 

Execution Copy

 

COMMON SHARE PURCHASE AGREEMENT

 

COMMON SHARE PURCHASE AGREEMENT (the “Agreement”),
dated as of May 7, 2019 by and between APTOSE BIOSCIENCES INC., a corporation organized under the laws of Canada (the “Company”),
and ASPIRE CAPITAL FUND, LLC, an Illinois limited liability company (the “Buyer”). Capitalized terms
used herein and not otherwise defined herein are defined in Section 10 hereof.

 

WHEREAS:

 

Subject to the terms and conditions set forth in
this Agreement, the Company wishes to sell to the Buyer, and the Buyer wishes to buy from the Company, up to Twenty Million Dollars
($20,000,000) of common shares of the Company without par value (the “Common Shares”). The Common Shares to
be purchased hereunder are referred to herein as the “Purchase Shares.”

 

NOW THEREFORE, the Company and the Buyer
hereby agree as follows:

 

		1.	PURCHASE OF COMMON SHARES. 

 

Subject to the terms and conditions set forth in
this Agreement, the Company has the right to sell to the Buyer, and the Buyer has the obligation to purchase from the Company,
Purchase Shares as follows:

 

(a)       Commencement
of Purchases of Common Shares. Any time after Commencement (as defined below), the purchase and sale of Purchase Shares hereunder
shall occur from time to time upon written notices by the Company to the Buyer on the terms and conditions as set forth herein
following the satisfaction of the conditions (the “Commencement”) as set forth in Sections 6 and 7 below (the
date of satisfaction of such conditions, the “Commencement Date”).

 

(b)       The
Company’s Right to Require Regular Purchases. Subject to the terms and conditions of this Agreement, on any given Business
Day after the Commencement Date, the Company shall have the right but not the obligation to direct the Buyer by its delivery to
the Buyer of a Purchase Notice from time to time, and the Buyer thereupon shall have the obligation, to buy the number of Purchase
Shares specified in such notice, up to 200,000 Purchase Shares, on such Business Day (as long as such notice is delivered on or
before 5:00 p.m. Eastern time on such Business Day) (each such purchase, a “Regular Purchase”) at the Purchase
Price on the Purchase Date; however, in no event shall the Purchase Amount of a Regular Purchase exceed Five Hundred Thousand Dollars
($500,000) per Business Day, unless the Buyer and the Company mutually agree. The Company and the Buyer may mutually agree to increase
the number of Purchase Shares that may be sold per Regular Purchase to as much as an additional 2,000,000 Purchase Shares per Business
Day. The Company may deliver additional Purchase Notices to the Buyer from time to time The share amounts in this Section 1(b)
shall be appropriately adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or
other similar transaction.

 

     

     

    

(c)       VWAP
Purchases. Subject to the terms and conditions of this Agreement, in addition to purchases of Purchase Shares as described
in Section 1(b) above, with prior written notice (as long as such notice is delivered on or before 5:00 p.m. Eastern time on the
Business Day immediately preceding the VWAP Purchase Date, the Company shall also have the right but not the obligation to direct
the Buyer by the Company’s delivery to the Buyer of a VWAP Purchase Notice from time to time, and the Buyer thereupon shall
have the obligation, to buy the VWAP Purchase Share Percentage of the trading volume of the Common Shares on the VWAP Purchase
Date up to the VWAP Purchase Share Volume Maximum on the VWAP Purchase Date (each such purchase, a “VWAP Purchase”)
at the VWAP Purchase Price. The Company may deliver a VWAP Purchase Notice to the Buyer on or before 5:00 p.m. Eastern time on
a date on which the Company also submitted a Purchase Notice for a Regular Purchase of at least 200,000 Purchase Shares to the
Buyer. The share amount in the prior sentence shall be appropriately adjusted for any reorganization, recapitalization, non-cash
dividend, stock split, reverse stock split, or other similar transaction. A VWAP Purchase shall automatically be deemed completed
at such time on the VWAP Purchase Date that the Sale Price falls below the VWAP Minimum Price Threshold; in such circumstance,
the VWAP Purchase Amount shall be calculated using (i) the VWAP Purchase Share Percentage of the aggregate shares traded on the
U.S. Market for such portion of the VWAP Purchase Date prior to the time that the Sale Price fell below the VWAP Minimum Price
Threshold and (ii) a VWAP Purchase Price calculated using the volume weighted average price of Common Shares sold during such portion
of the VWAP Purchase Date prior to the time that the Sale Price fell below the VWAP Minimum Price Threshold. Upon completion of
each VWAP Purchase Date, the Buyer shall submit to the Company a confirmation of the VWAP Purchase in form and substance reasonably
acceptable to the Company. As soon as reasonably practicable after receiving payment from the Buyer for the Purchase Shares purchased
under the VWAP Purchase, the Company shall deliver to the Company’s Transfer Agent a direction to immediately issue to the
Buyer the number of Purchase Shares that the Buyer has the obligation to buy pursuant to the VWAP Purchase Notice. The Company
may deliver additional VWAP Purchase Notices to the Buyer from time to time so long as the most recent purchase has been completed.

 

(d)       Payment
for Purchase Shares. For each Regular Purchase, the Buyer shall pay to the Company an amount equal to the Purchase Amount as
full payment for such Purchase Shares via wire transfer of immediately available funds on the same Business Day as the Regular
Purchase and, as soon as reasonably practicable after receiving payment from the Buyer for the Purchase Shares purchased under
such Regular Purchase, the Company shall deliver to the Company’s Transfer Agent a direction to immediately issue to the
Buyer the number of Purchase Shares that the Buyer has the obligation to buy pursuant to the Purchase Notice. For each VWAP Purchase,
the Buyer shall pay to the Company an amount equal to the VWAP Purchase Amount as full payment for such Purchase Shares via wire
transfer of immediately available funds on the second Business Day following the VWAP Purchase Date. All payments made under this
Agreement shall be made in lawful money of the United States of America via wire transfer of immediately available funds to such
account as the Company may from time to time designate by written notice in accordance with the provisions of this Agreement. Whenever
any amount expressed to be due by the terms of this Agreement is due on any day that is not a Business Day, the same shall instead
be due on the next succeeding day that is a Business Day.

 

(e)       Purchase
Price Floor. The Company and the Buyer shall not effect any sales under this Agreement on any Purchase Date where the Closing
Sale Price is less than the Floor Price. “Floor Price” means $0.25 per Common Share, which shall be appropriately
adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction.

 

(f)       Records
of Purchases. The Buyer and the Company shall each maintain records showing the remaining Available Amount at any given time
and the dates and Purchase Amounts for each purchase, or shall use such other method reasonably satisfactory to the Buyer and the
Company to reconcile the remaining Available Amount.

 

    	 	-2-	 

     

    

(g)       Taxes.
The Company shall pay any and all transfer, stamp or similar taxes that may be payable with respect to the issuance and delivery
of any Common Shares to the Buyer made under this Agreement.

 

(h)       Compliance
with Exchanges Rules. Notwithstanding anything in this Agreement to the contrary, and in addition to the limitations set forth
in Sections 1(e) and 1(i), the total number of Common Shares that may be issued under this Agreement, including the Commitment
Shares (as defined in Section 4(e) hereof), shall be limited to 8,748,525 Common Shares (the “Exchange Cap”),
which equals 19.99% of the Company’s outstanding Common Shares as of the date hereof, unless disinterested shareholder approval
is obtained to issue more than such 19.99%. The Exchange Cap shall be appropriately adjusted for any reorganization, recapitalization,
non-cash dividend, stock split, reverse-stock split or other similar transaction. The foregoing limitation shall not apply if shareholder
approval has not been obtained and at any time the Exchange Cap is reached and at all times thereafter the average price paid for
all shares issued under this Agreement is equal to or greater than $2.10 (the “Minimum Price”), a price equal
to the lower of (a) the Closing Sale Price immediately preceding the execution of this Agreement or (b) the arithmetic average
of the five (5) Closing Sale Prices for the Common Shares immediately preceding the execution of this Agreement (in such circumstance,
for purposes of the Exchanges, the transaction contemplated hereby would not be “below market” and the Exchange Cap
would not apply). The Minimum Price shall be appropriately adjusted for any reorganization, recapitalization, non-cash dividend,
stock split, reverse stock split or other similar transaction. Notwithstanding anything to the contrary in this Agreement or otherwise,
the Company shall not be required or permitted to issue, and the Buyer shall not be required to purchase, any Common Shares under
this Agreement if such issuance would breach the Company's obligations under the rules or regulations of the Exchanges. The Company
may, in its sole discretion, determine whether to obtain disinterested shareholder approval to issue more than 19.99% of its outstanding
Common Shares hereunder.

 

(i)       Beneficial Ownership Limitation. The Company shall not issue, and the Buyer shall not purchase any Common Shares under this
Agreement, if such shares proposed to be issued and sold, when aggregated with all other Common Shares then owned beneficially
(as calculated pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended (the “1934 Act”)
and Rule 13d-3 promulgated thereunder) by the Buyer and its affiliates would result in the beneficial ownership by the Buyer and
its affiliates of more than 9.99% of the then issued and outstanding Common Shares, or if such shares proposed to be issued and
sold would result in a change of control under the rules of the TSX.

 

(j)       Material
Non-Public Information Restriction. Notwithstanding anything in this Agreement to the contrary, during any period in which
the Company is in possession of material non-public information, the Company and the Buyer agree that (i) no purchase of Purchase
Shares will take place, (ii) the Company shall not request the purchase of any Purchase Shares, and (iii) the Buyer shall not be
obligated to purchase any Purchase Shares.

 

(k)       TSX
Personal Information Form. The Company shall not issue and the Buyer shall not purchase any Common Shares under this Agreement
if such shares proposed to be issued and sold, when aggregated with all other Common Shares then owned beneficially by the Buyer
and its affiliates would result in the beneficial ownership by the Buyer and its affiliates of more than 9.99% of the then issued
and outstanding Common Shares unless and until a personal information form is filed and precleared by the TSX in accordance with
its rules. Accordingly, this Agreement may not result in the Buyer or any of its affiliates becoming an insider of the Company
(as such term is defined under the rules of the TSX) unless and until a personal information form is filed and precleared by the
TSX in accordance with its rules.

 

    	 	-3-	 

     

    

2.       BUYER’S
REPRESENTATIONS AND WARRANTIES.

 

The Buyer represents and warrants to the Company
that as of the date hereof and as of the Commencement Date:

 

(a)       Investment
Purpose. The Buyer is entering into this Agreement and acquiring the Commitment Shares and the Purchase Shares (the Purchase
Shares and the Commitment Shares are collectively referred to herein as the “Securities”), for its own account
for investment only and not with a view towards, or for resale in connection with, the public sale or distribution thereof; provided
however, by making the representations herein, the Buyer does not agree to hold any of the Securities for any minimum or other
specific term. Notwithstanding anything to the contrary in this Agreement, the Company and the Buyer each acknowledge and agree
that any resale or solicitation for resale of Purchase Shares by the Buyer pursuant to this Agreement shall be made solely in the
United States and no resale of Purchase Shares will be carried out by the Buyer in Canada or on the TSX.

 

(b)       Accredited
Investor Status. The Buyer is an “accredited investor” as that term is defined in Rule 501(a)(3) of Regulation
D under the 1933 Act.

 

(c)       [Intentionally
Omitted.]

 

(d)       Information.
The Buyer has been furnished with all materials relating to the business, finances and operations of the Company and materials
relating to the offer and sale of the Securities that have been reasonably requested by the Buyer, including, without limitation,
the SEC Documents (as defined in Section 3(f) hereof). The Buyer understands that its investment in the Securities involves a high
degree of risk. The Buyer (i) is able to bear the economic risk of an investment in the Securities including a total loss, (ii)
has such knowledge and experience in financial and business matters that it is capable of evaluating the merits and risks of the
proposed investment in the Securities and (iii) has had an opportunity to ask questions of and receive answers from the officers
of the Company concerning the financial condition and business of the Company, the terms and conditions of the offering of the
Securities and other matters related to an investment in the Securities. Neither such inquiries nor any other due diligence investigations
conducted by the Buyer or its representatives shall modify, amend or affect the Buyer’s right to rely on the Company’s
representations and warranties contained in Section 3 below. The Buyer has sought such accounting, legal and tax advice as it has
considered necessary to make an informed investment decision with respect to its acquisition of the Securities. The Buyer acknowledges
that there may be material United States and Canadian tax consequences to it of the acquisition, holding and disposition of the
Securities, it is the Buyer’s sole responsibility to determine such tax consequences for the Buyer, and the Company has not
made any representation or warranty to the Buyer with respect to such tax consequences.

 

(e)       No
Governmental Review. The Buyer understands that no United States federal or state agency or any other government or governmental
agency has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of the investment
in the Securities nor have such authorities passed upon or endorsed the merits of the offering of the Securities.

 

    	 	-4-	 

     

    

(f)       [Intentionally
Omitted.]

 

(g)       Organization.
The Buyer is a limited liability company duly organized and validly existing in good standing under the laws of the jurisdiction
in which it is organized, and has the requisite organizational power and authority to own its properties and to carry on its business
as now being conducted.

 

(h)       Validity;
Enforcement. This Agreement has been duly and validly authorized, executed and delivered on behalf of the Buyer and is a valid
and binding agreement of the Buyer enforceable against the Buyer in accordance with its terms, subject as to enforceability to
(i) general principles of equity and to applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other similar
laws relating to, or affecting generally, the enforcement of applicable creditors’ rights and remedies and (ii) public policy
underlying any law, rule or regulation (including any federal or state securities law, rule or regulation) with regards to indemnification,
contribution or exculpation. The execution and delivery of the Transaction Documents (as defined in Section 3(b) hereof) by the
Buyer and the consummation by it of the transactions contemplated hereby and thereby do not conflict with the Buyer’s certificate
of organization or operating agreement or similar documents, and do not require further consent or authorization by the Buyer,
its managers or its members.

 

(i)       Residency.
The Buyer is of the State of Illinois.

 

(j)       No
Prior Short Selling. The Buyer represents and warrants to the Company that at no time prior to the date of this Agreement has
any of the Buyer, its agents, representatives or affiliates engaged in or effected, in any manner whatsoever, directly or indirectly,
any (i) “short sale” (as such term is defined in Section 242.200 of Regulation SHO of the 1934 Act) of the Common Shares
or (ii) hedging transaction, which establishes a net short position with respect to the Common Shares.

 

3.       REPRESENTATIONS
AND WARRANTIES OF THE COMPANY. 

 

The Company represents and warrants to the Buyer
that as of the date hereof and as of the Commencement Date:

 

(a)       Organization
and Qualification. The Company and its “Subsidiaries” (which for purposes of this Agreement means any entity in
which the Company, directly or indirectly, owns more than 50% of the voting stock or capital stock or other similar equity interests)
are corporations or limited liability companies duly organized and validly existing in good standing under the laws of the jurisdiction
in which they are incorporated or organized, and have the requisite corporate or organizational power and authority to own their
properties and to carry on their business as now being conducted. Each of the Company and its Subsidiaries is duly qualified as
a foreign corporation or limited liability company to do business and is in good standing in every jurisdiction in which its ownership
of property or the nature of the business conducted by it makes such qualification necessary, except to the extent that the failure
to be so qualified or be in good standing would not reasonably be expected to have a Material Adverse Effect. As used in this Agreement,
“Material Adverse Effect” means any material adverse effect on any of: (i) the business, properties, assets, operations,
results of operations or financial condition of the Company and its Subsidiaries, if any, taken as a whole, or (ii) the authority
or ability of the Company to perform its obligations under the Transaction Documents. The Company has no material Subsidiaries
except as set forth on Schedule 3(a).

 

    	 	-5-	 

     

    

(b)       Authorization;
Enforcement; Validity. (i) The Company has the requisite corporate power and authority to enter into and perform its obligations
under this Agreement, the Registration Rights Agreement and each of the other agreements entered into by the parties on the Commencement
Date and attached hereto as exhibits to this Agreement (collectively, the “Transaction Documents”), and to issue
the Securities in accordance with the terms hereof and thereof, (ii) the execution and delivery of the Transaction Documents by
the Company and the consummation by it of the transactions contemplated hereby and thereby, including without limitation, the issuance
of the Commitment Shares and the reservation for issuance and the issuance of the Purchase Shares issuable under this Agreement,
have been duly authorized by the Company’s Board of Directors or duly authorized committee thereof, do not conflict with
the Company’s Certificate of Incorporation or Bylaws (as defined below), and do not require further consent or authorization
by the Company, its Board of Directors, except as set forth in this Agreement, or its shareholders, (iii) this Agreement has been,
and each other Transaction Document shall be on the Commencement Date, duly executed and delivered by the Company and (iv) this
Agreement constitutes, and each other Transaction Document upon its execution on behalf of the Company, shall constitute, the valid
and binding obligations of the Company enforceable against the Company in accordance with their terms, except as such enforceability
may be limited by (y) general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation
or similar laws relating to, or affecting generally, the enforcement of creditors' rights and remedies and (z) public policy underlying
any law, rule or regulation (including any federal or state securities law, rule or regulation) with regards to indemnification,
contribution or exculpation. The Board of Directors of the Company or duly authorized committee thereof has approved the resolutions
(the “Signing Resolutions”) substantially in the form as set forth as Exhibit B attached hereto to authorize
this Agreement and the transactions contemplated hereby. The Signing Resolutions are valid, in full force and effect and have not
been modified or supplemented in any material respect. The Company has delivered to the Buyer a true and correct copy of the Signing
Resolutions as approved by the Board of Directors of the Company.

 

(c)       Capitalization.
As of the date hereof, the authorized capital of the Company consists of an unlimited number of Common Shares without par value,
of which as of the date hereof, 43,764,509 shares are issued and outstanding, zero shares are held as treasury shares, 7,658,789
shares are reserved for future issuance pursuant to the Company’s equity incentive plans, of which approximately 1,880,301
shares remain available for future option grants or stock awards. All of such outstanding shares have been, or upon issuance will
be, validly issued and are fully paid and non-assessable. Except as disclosed in Schedule 3(c), (i) no shares of the Company’s
authorized capital are subject to preemptive rights or any other similar rights or any liens or encumbrances suffered or permitted
by the Company, (ii) there are no outstanding debt securities of the Company or any of its Subsidiaries, (iii) there are no outstanding
options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or
rights convertible into, any common shares of the Company or any of its Subsidiaries, or contracts, commitments, understandings
or arrangements by which the Company or any of its Subsidiaries is or may become bound to issue additional shares of the Company
or any of its Subsidiaries or options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever
relating to, or securities or rights convertible into, any shares of the Company or any of its Subsidiaries, (iv) there are no
material agreements or arrangements under which the Company or any of its Subsidiaries is obligated to register the sale of any
of their securities under the 1933 Act (except the Registration Rights Agreement), (v) there are no outstanding securities or instruments
of the Company or any of its Subsidiaries which contain any redemption or similar provisions, and there are no contracts, commitments,
understandings or arrangements by which the Company or any of its Subsidiaries is or may become bound to redeem a security of the
Company or any of its Subsidiaries, (vi) there are no securities or instruments containing anti-dilution or similar provisions
that will be triggered by the issuance of the Securities as described in this Agreement and (vii) the Company does not have any
stock appreciation rights or “phantom stock” plans or agreements or any similar plan or agreement. The Company has
furnished or made available to the Buyer true and correct copies of the Company’s Certificate of Incorporation, as amended
and as in effect on the date hereof (the “Certificate of Incorporation”), and the Company’s Bylaws, as
amended and as in effect on the date hereof (the “Bylaws”).

 

    	 	-6-	 

     

    

(d)       Issuance
of Securities. The Commitment Shares have been duly authorized and, upon issuance in accordance with the terms hereof, the
Commitment Shares shall be (i) validly issued, fully paid and non-assessable and (ii) free from all taxes, liens and charges with
respect to the issuance thereof. Upon issuance and payment therefore in accordance with the terms and conditions of this Agreement,
the Purchase Shares shall be validly issued, fully paid and non-assessable and free from all taxes, liens and charges with respect
to the issue thereof, with the holders being entitled to all rights accorded to a holder of Common Shares.

 

(e)       No
Conflicts. Except as disclosed in Schedule 3(e), the execution, delivery and performance of the Transaction Documents by the
Company and the consummation by the Company of the transactions contemplated hereby and thereby (including, without limitation,
the reservation for issuance and issuance of the Purchase Shares) will not (i) result in a violation of the Certificate of Incorporation
or the Bylaws or (ii)constitute a default (or an event which with notice or lapse of time or both would become a default) under,
or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument
to which the Company or any of its Subsidiaries is a party, or result, to the Company’s knowledge, in a violation of any
law, rule, regulation, order, judgment or decree (including federal and state securities laws and regulations and the rules and
regulations of the Exchanges applicable to the Company or any of its Subsidiaries) or by which any property or asset of the Company
or any of its Subsidiaries is bound or affected, except in the case of defaults, terminations, amendments, accelerations, cancellations
and violations under clause (ii), which would not reasonably be expected to result in a Material Adverse Effect. Except as disclosed
in Schedule 3(e), neither the Company nor its Subsidiaries is in violation of any term of or in default under its Certificate of
Incorporation or Bylaws or their organizational charter or bylaws, respectively. Except as disclosed in Schedule 3(e), neither
the Company nor any of its Subsidiaries is in violation of any term of or is in default under any material contract, agreement,
mortgage, indebtedness, indenture, instrument, judgment, decree or order or any statute, rule or regulation applicable to the Company
or its Subsidiaries, except for possible violations, defaults, terminations or amendments that would not reasonably be expected
to have a Material Adverse Effect. The business of the Company and its Subsidiaries is not being conducted, and shall not be conducted,
in violation of any law, ordinance, or regulation of any governmental entity, except for possible violations, the sanctions for
which either individually or in the aggregate would not reasonably be expected to have a Material Adverse Effect. Except as specifically
contemplated by this Agreement, reporting obligations under the 1934 Act, or as required under the 1933 Act or applicable state
securities laws or the filing of a Listing of Additional Shares Notification Form with the U.S. Exchange, the Company is not required
to obtain any consent, authorization or order of, or make any filing or registration with, any court or governmental agency or
any regulatory or self-regulatory agency in order for it to execute, deliver or perform any of its obligations under or contemplated
by the Transaction Documents in accordance with the terms hereof or thereof. Except as disclosed in Schedule 3(e) and for reporting
obligations under the 1934 Act, all consents, authorizations, orders, filings and registrations which the Company is required to
obtain pursuant to the preceding sentence shall be obtained or effected on or prior to the Commencement Date. Except as disclosed
in Schedule 3(e), the Company is not subject to any notices or actions from or to the Exchanges other than routine matters incident
to listing on the Exchanges and not involving a violation of the rules of the Exchanges. Except as disclosed in Schedule 3(e),
to the Company’s knowledge, the U.S. Exchange has not commenced any delisting proceedings against the Company.

 

    	 	-7-	 

     

    

(f)       SEC
Documents; Financial Statements. Except as disclosed in Schedule 3(f), since December 31, 2017, the Company has filed all reports,
schedules, forms, statements and other documents required to be filed by it with the SEC pursuant to the reporting requirements
of the 1934 Act (all of the foregoing filed prior to the date hereof and all exhibits included therein and financial statements
and schedules thereto and documents incorporated by reference therein being hereinafter referred to as the “SEC Documents”).
As of their respective dates (except as they have been correctly amended), the SEC Documents complied in all material respects
with the requirements of the 1934 Act and the rules and regulations of the SEC promulgated thereunder applicable to the SEC Documents,
and none of the SEC Documents, at the time they were filed with the SEC (except as they may have been properly amended), contained
any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order
to make the statements therein, in light of the circumstances under which they were made, not misleading. As of their respective
dates (except as they have been properly amended), the financial statements of the Company included in the SEC Documents complied
as to form in all material respects with applicable accounting requirements and the published rules and regulations of the SEC
with respect thereto. Such financial statements have been prepared in accordance with International Financial Reporting Standards
as issued by the International Accounting Standards Board, consistently applied, during the periods involved (except (i) as may
be otherwise indicated in such financial statements or the notes thereto or (ii) in the case of unaudited interim statements, to
the extent they may exclude footnotes or may be condensed or summary statements) and fairly present in all material respects the
financial position of the Company as of the dates thereof and the results of its operations and cash flows for the periods then
ended (subject, in the case of unaudited statements, to normal year-end audit adjustments). Except as disclosed in Schedule 3(f)
or routine correspondence, such as comment letters and notices of effectiveness in connection with previously filed registration
statements or periodic reports publicly available on EDGAR, to the Company’s knowledge, the Company or any of its Subsidiaries
are not on the date hereof the subject of any inquiry, investigation or action by the SEC.

 

(g)       Absence
of Certain Changes. Except as disclosed in Schedule 3(g), since December 31, 2018, there has been no material adverse change
in the business, properties, operations, financial condition or results of operations of the Company or its Subsidiaries taken
as a whole. For purposes of this Agreement, neither a decrease in cash or cash equivalents or in the market price of the Common
Shares nor losses incurred in the ordinary course of the Company’s business shall be deemed or considered a material adverse
change. The Company has not taken any steps, and does not currently expect to take any steps, to seek protection pursuant to any
Bankruptcy Law nor does the Company or any of its Subsidiaries have any knowledge or reason to believe that its creditors intend
to initiate involuntary bankruptcy or insolvency proceedings. The Company is financially solvent and is generally able to pay its
debts as they become due.

 

(h)       Absence
of Litigation. Except as disclosed in Schedule 3(h), to the Company’s knowledge, there is no action, suit, proceeding,
inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending
or, to the knowledge of the Company or any of its Subsidiaries, threatened against the Company, the Common Shares or any of the
Company’s Subsidiaries or any of the Company’s or the Company’s Subsidiaries’ officers or directors in
their capacities as such, which could reasonably be expected to have a Material Adverse Effect (each, an “Action”).
A description of each such Action, if any, is set forth in Schedule 3(h).

 

    	 	-8-	 

     

    

(i)       Acknowledgment
Regarding Buyer’s Status. The Company acknowledges and agrees that the Buyer is acting solely in the capacity of arm’s
length purchaser with respect to the Transaction Documents and the transactions contemplated hereby and thereby. The Company further
acknowledges that the Buyer is not acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with
respect to the Transaction Documents and the transactions contemplated hereby and thereby and any advice given by the Buyer or
any of its representatives or agents in connection with the Transaction Documents and the transactions contemplated hereby and
thereby is merely incidental to the Buyer’s purchase of the Securities. The Company further represents to the Buyer that
the Company’s decision to enter into the Transaction Documents has been based solely on the independent evaluation by the
Company and its representatives and advisors.

 

(j)       Intellectual
Property Rights. To the Company’s knowledge, the Company and its Subsidiaries own or possess adequate rights or licenses
to use all material trademarks, trade names, service marks, service mark registrations, service names, patents, patent rights,
copyrights, inventions, licenses, approvals, governmental authorizations, trade secrets and other intellectual property rights
(collectively, “Intellectual Property”) necessary to conduct their respective businesses as now conducted, except
as set forth in Schedule 3(j) or to the extent that the failure to own, possess, license or otherwise hold adequate rights to use
Intellectual Property would not, individually or in the aggregate, have a Material Adverse Effect. Except as disclosed in Schedule
3(j), to the Company’s knowledge, none of the Company’s active and registered Intellectual Property have expired or
terminated, or, by the terms and conditions thereof, will expire or terminate within two years from the date of this Agreement,
except as would not reasonably be expected to have a Material Adverse Effect. The Company and its Subsidiaries do not have any
knowledge of any infringement by the Company or its Subsidiaries of any Intellectual Property of others and, except as set forth
on Schedule 3(j), there is no claim, action or proceeding being made or brought against, or to the Company’s knowledge, being
threatened against, the Company or its Subsidiaries regarding Intellectual Property, which could reasonably be expected to have
a Material Adverse Effect.

 

(k)       Environmental
Laws. To the Company’s knowledge, the Company and its Subsidiaries (i) are in material compliance with any and all applicable
foreign, federal, state, provincial and local laws and regulations relating to the protection of human health and safety or the
environment with respect to hazardous or toxic substances or wastes, pollutants or contaminants (“Environmental Laws”),
(ii) have received all material permits, licenses or other approvals required of them under applicable Environmental Laws to conduct
their respective businesses and (iii) are in material compliance with all terms and conditions of any such permit, license or approval,
except where, in each of the three foregoing clauses, the failure to so comply or receive such approvals would not reasonably be
expected to have, individually or in the aggregate, a Material Adverse Effect.

 

(l)       Title.
The Company and its Subsidiaries have good and marketable title to all personal property owned by them that is material to the
business of the Company and its Subsidiaries, in each case free and clear of all liens, encumbrances and defects except such as
are described in Schedule 3(l) or such as do not materially affect the value of such property and do not interfere with the use
made and proposed to be made of such property by the Company and any of its Subsidiaries or would not reasonably be expected to
have, individually or in the aggregate, a Material Adverse Effect. Any real property and facilities held under lease by the Company
and any of its Subsidiaries, to the Company’s knowledge, are held by them under valid, subsisting and enforceable leases
with such exceptions as are not material and do not interfere with the use made and proposed to be made of such property and buildings
by the Company and its Subsidiaries.

 

    	 	-9-	 

     

    

(m)       Insurance.
The Company and each of its Subsidiaries are insured by insurers of recognized financial responsibility against such losses and
risks and in such amounts as management of the Company believes to be reasonable and customary in the businesses in which the Company
and its Subsidiaries are engaged. To the Company’s knowledge, since December 31, 2016, neither the Company nor any such Subsidiary
has been refused any insurance coverage sought or applied for and neither the Company nor any such Subsidiary, to the Company’s
knowledge, will be unable to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage
from similar insurers as may be necessary to continue its business at a cost that would reasonably be expected to have a Material
Adverse Effect.

 

(n)       Regulatory
Permits. The Company and its Subsidiaries possess all material certificates, authorizations and permits issued by the appropriate
federal, state, provincial, local or foreign regulatory authorities necessary to conduct their respective businesses as currently
conducted, except when the failure to so possess such certificates, authorizations or permits could not reasonably be expected
to have, individually or in the aggregate, a Material Adverse Effect, and neither the Company nor any such Subsidiary has received
any written notice of proceedings relating to the revocation or modification of any such material certificate, authorization or
permit.

 

(o)       Tax
Status. The Company and each of its Subsidiaries has made or filed all federal, provincial and state income and all other material
tax returns, reports and declarations required by any jurisdiction to which it is subject (unless and only to the extent that the
Company and each of its Subsidiaries has set aside on its books reserves reasonably adequate for the payment of all unpaid and
unreported taxes or filed valid extensions) and has paid all taxes and other governmental assessments and charges that are material
in amount, shown or determined to be due on such returns, reports and declarations, except those being contested in good faith
and has set aside on its books reserves reasonably adequate for the payment of all taxes for periods subsequent to the periods
to which such returns, reports or declarations apply. To the Company’s knowledge, there are no unpaid taxes in any material
amount claimed to be due by the taxing authority of any jurisdiction.

 

(p)       Transactions
With Affiliates. Except as set forth on Schedule 3(p) and other than the grant or exercise of stock options or any other equity
securities offered pursuant to duly adopted stock or incentive compensation plans as disclosed on Schedule 3(c), none of the officers,
directors or employees of the Company is on the date hereof a party to any transaction with the Company or any of its Subsidiaries
(other than for services as employees, officers and directors and reimbursement for expenses incurred on behalf of the Company),
including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental
of real or personal property to or from, or otherwise requiring payments to or from any officer, director or such employee or,
to the knowledge of the Company, any corporation, partnership, trust or other entity in which any officer, director, or any such
employee has a material interest or is an officer, director, trustee or general partner.

 

    	 	-10-	 

     

    

(q)       Application
of Takeover Protections. The Company and its board of directors have taken or will take prior to the Commencement Date all
necessary action, if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including
any distribution under a rights agreement) or other similar anti-takeover provision under the Certificate of Incorporation or the
laws of the jurisdiction of its incorporation which is or could become applicable to the Buyer as a result of the transactions
contemplated by this Agreement, including, without limitation, the Company’s issuance of the Securities and the Buyer’s
ownership of the Securities.

 

(r)       Registration
Statement. The Shelf Registration Statement (as defined in Section 4(a) hereof) has been declared effective by the SEC, and
no stop order has been issued or is pending or, to the knowledge of the Company, threatened by the SEC with respect thereto. As
of the date hereof, the Company has a dollar amount of securities registered and unsold under the Shelf Registration Statement,
which is not less than the sum of (i) the Available Amount and (ii) the market value of the Commitment Shares on the date hereof.

 

4.       COVENANTS.

 

(a)       Filing
of Form 8-K and Prospectus Supplement. The Company agrees that it shall, within the time required under the 1934 Act, file
a Current Report on Form 8-K disclosing this Agreement and the transaction contemplated hereby. The Company shall file within two
(2) Business Days from the Commencement Date a prospectus supplement to the Company’s existing shelf registration statement
on Form S-3 (File No. 333-230218, the “Shelf Registration Statement”) covering the sale of the Commitment Shares
and Purchase Shares (the “Prospectus Supplement”) in accordance with the terms of the Registration Rights Agreement
between the Company and the Buyer, dated as of the date hereof (the “Registration Rights Agreement”). its reasonable
best efforts to effective under the 1933 Act and available for sales of all Securities to the Buyer no longer qualifies to make
sales under the Shelf Registration Statement (which shall be understood to include the inability of the Company to immediately
register sales of Securities to the Buyer under the Shelf Registration Statement or any New Registration Statement pursuant to
General Instruction I.B.6 of Form S-3), (ii) the date on which all the Securities have been sold under this Agreement and no Available
Amount remains thereunder, or (iii) Agreement has been terminated. The Shelf Registration Statement (including any amendments or
supplements thereto and prospectuses or prospectus supplements, including the Prospectus Supplement, contained therein) shall not
contain any untrue statement of a material fact or omit to state a material fact required to be stated therein, or necessary to
make the statements therein, in the light of the circumstances under which they were made, not misleading.

 

(b)       Blue
Sky. The Company shall take such action, if any, as is reasonably necessary in order to obtain an exemption for or to qualify
(i) the initial sale of the Securities to the Buyer under this Agreement and (ii) any subsequent sale of the Securities by the
Buyer, in each case, under applicable securities or “Blue Sky” laws of the states of the United States in such states
as is reasonably requested by the Buyer from time to time, and shall provide evidence of any such action so taken to the Buyer
at its written request; provided, however, that the Company shall not be obligated to file any general consent to service
of process or to qualify as a foreign corporation or as a dealer in securities in any jurisdiction in which it is not so qualified
or to subject itself to taxation in respect of doing business in any jurisdiction in which it is not otherwise so subject.

 

    	 	-11-	 

     

    

(c)       Listing.
The Company shall promptly secure the listing of all of the Securities (subject to official notice of issuance) on the U.S. Exchange
and shall maintain such listing, so long as any other Common Shares shall be so listed. The Company shall use its reasonable best
efforts to maintain the Common Shares’ listing on the U.S. Exchange. Neither the Company nor any of its Subsidiaries shall
take any action that would be reasonably expected to result in the delisting or suspension of the Common Shares on the U.S. Exchange.
The Company shall pay all fees and expenses in connection with satisfying its obligations under this Section.

 

(d)       Limitation
on Short Sales and Hedging Transactions. The Buyer agrees that beginning on the date of this Agreement and ending on the date
of termination of this Agreement as provided in Section 11(k), the Buyer and its agents, representatives and affiliates shall not
in any manner whatsoever enter into or effect, directly or indirectly, any (i) “short sale” (as such term is defined
in Section 242.200 of Regulation SHO of the 1934 Act) of the Common Shares or (ii) hedging transaction, which establishes a net
short position with respect to the Common Shares.

 

(e)       Issuance
of Commitment Shares. In connection with the Commencement, the Company shall issue to the Buyer as consideration for the Buyer
entering into this Agreement 171,428 Common Shares (the “Commitment Shares”). The Commitment Shares shall be
issued without any restrictive legend whatsoever or prior sale requirement.

 

(f)       Due
Diligence. The Buyer shall have the right, from time to time as the Buyer may reasonably deem appropriate, to perform reasonable
due diligence on the Company during normal business hours and subject to reasonable prior notice to the Company. The Company and
its officers and employees shall provide information and reasonably cooperate with the Buyer in connection with any reasonable
request by the Buyer related to the Buyer’s due diligence of the Company, including, but not limited to, any such request
made by the Buyer in connection with (i) the filing of the prospectus supplement described in Section 4(a) hereof and (ii) the
Commencement; provided, however, that at no time is the Company required to disclose material nonpublic information to the Buyer
or breach any obligation of confidentiality or non-disclosure to a third party or make any disclosure that could cause a waiver
of attorney-client privilege. Except as may be required by law, court order or governmental authority, each party hereto agrees
not to disclose any Confidential Information of the other party to any third party and shall not use the Confidential Information
of such other party for any purpose other than in connection with, or in furtherance of, the transactions contemplated hereby.
Each party hereto acknowledges that the Confidential Information shall remain the property of the disclosing party and agrees that
it shall take all reasonable measures to protect the secrecy of any Confidential Information disclosed by the other party.

 

5.       TRANSFER
AGENT INSTRUCTIONS.

 

All of the Purchase Shares to be issued under this
Agreement shall be issued without any restrictive legend unless the Buyer expressly consents otherwise. The Company shall issue
irrevocable instructions to the Transfer Agent, and any subsequent transfer agent, to issue Common Shares in the name of the Buyer
for the Purchase Shares (the “Irrevocable Transfer Agent Instructions”). The Company warrants to the Buyer that
no instruction other than the Irrevocable Transfer Agent Instructions referred to in this Section 5, will be given by the Company
to the Transfer Agent with respect to the Purchase Shares and that the Commitment Shares and the Purchase Shares shall otherwise
be freely transferable on the books and records of the Company as and to the extent provided in this Agreement and the Registration
Rights Agreement.

 

    	 	-12-	 

     

    

		6.	CONDITIONS TO THE COMPANY’S RIGHT TO COMMENCE

SALES OF COMMON SHARES UNDER THIS AGREEMENT.

 

The right of the Company hereunder to commence sales
of the Purchase Shares is subject to the satisfaction of each of the following conditions on or before the Commencement Date (the
date that the Company may begin sales of Purchase Shares):

 

(a)       The
Buyer shall have executed each of the Transaction Documents and delivered the same to the Company;

 

(b)       The
representations and warranties of the Buyer shall be true and correct as of the Commencement Date as though made at that time (except
for representations and warranties that speak as of a specific date, which shall be true and correct in all material respects as
of such specific date) and the Buyer shall have performed, satisfied and complied in all material respects with the covenants and
agreements required by this Agreement to be performed, satisfied or complied with by the Buyer at or prior to the Commencement
Date; and

 

(c)       The
Prospectus Supplement shall have been delivered to the Buyer and no stop order with respect to the registration statement covering
the sale of shares to the Buyer shall be pending or, to the knowledge of the Company, threatened by the SEC.

 

		7.	CONDITIONS TO THE BUYER’S OBLIGATION TO MAKE PURCHASES OF SHARES OF COMMON SHARES.

 

The obligation of the Buyer to buy Purchase Shares
under this Agreement is subject to the satisfaction of each of the following conditions on or before the Commencement Date (the
date that the Company may begin sales of Purchase Shares) and once such conditions have been initially satisfied, there shall not
be any ongoing obligation to satisfy such conditions after the Commencement has occurred:

 

(a)       The
Company shall have executed each of the Transaction Documents and delivered the same to the Buyer;

 

(b)       The
Company shall have received all approvals and authorizations as necessary and applicable by the TSX and the U.S. Exchange to issue
the shares hereunder;

 

(c)       The
Common Shares shall be authorized for quotation on the U.S. Exchange, trading in the Common Shares shall not have been within the
last 365 days suspended by the SEC or the U.S. Exchange, other than a general halt in trading in the Common Shares by the U.S.
Exchange under halt codes indicating pending or released material news, and the Securities shall be approved for listing upon the
U.S. Exchange;

 

(d)       The
Buyer shall have received opinions of the Company’s Canadian and United States legal counsel, each dated as of the Commencement
Date and in customary form and substance;

 

    	 	-13-	 

     

    

(e)       The
representations and warranties of the Company shall be true and correct in all material respects (except to the extent that any
of such representations and warranties is already qualified as to materiality in Section 3 above, in which case, such representations
and warranties shall be true and correct without further qualification) as of the date of this Agreement and as of the Commencement
Date as though made at that time (except for representations and warranties that speak as of a specific date, which shall be true
and correct in all material respects as of such specific date) and the Company shall have performed, satisfied and complied in
all material respects with the covenants, agreements and conditions required by the Transaction Documents to be performed, satisfied
or complied with by the Company at or prior to the Commencement Date. The Buyer shall have received a certificate, executed by
the CEO, President or CFO of the Company, dated as of the Commencement Date, to the foregoing effect in the form attached hereto
as Exhibit A;

 

(f)       The
Board of Directors of the Company or a duly authorized committee thereof shall have adopted resolutions substantially in the form
attached hereto as Exhibit B which shall be in full force and effect without any amendment or supplement thereto as of the
Commencement Date;

 

(g)       As
of the Commencement Date, the Company shall have reserved out of its authorized and unissued Common shares the Purchase Shares
solely for the purpose of effecting future purchases of Purchase Shares hereunder;

 

(h)       The
Irrevocable Transfer Agent Instructions, in form acceptable to the Buyer shall have been delivered to and acknowledged in writing
by the Company and the Buyer and have been delivered to the Transfer Agent;

 

(i)       The
Company shall have delivered to the Buyer a certificate evidencing the incorporation and good standing of the Company under the
laws of Canada issued by Industry Canada as of a date within ten (10) Business Days of the Commencement Date;

 

(j)       [Intentionally
Omitted.];

 

(k)       The
Company shall have delivered to the Buyer a secretary’s certificate executed by the Secretary of the Company, dated as of
the Commencement Date, in the form attached hereto as Exhibit C;

 

(l)       The
Shelf Registration Statement shall have been declared effective under the 1933 Act by the SEC and no stop order with respect thereto
shall be pending or, to the knowledge of the Company, threatened by the SEC. The Company shall have prepared and delivered to the
Buyer a final and complete form of Prospectus Supplement, dated and current as of the Commencement Date, to be used in connection
with any issuances of any Commitment Shares or any Purchase Shares to the Buyer, and to be filed by the Company within two (2)
Business Days after the Commencement Date pursuant to Rule 424(b) under the 1933 Act. The Company shall have made all filings under
all applicable federal and state securities laws necessary to consummate the issuance of the Commitment Shares and the Purchase
Shares pursuant to this Agreement in compliance with such laws;

 

(m)       No
Event of Default has occurred and is continuing, or any event which, after notice and/or lapse of time, would become an Event of
Default has occurred;

 

(n)       On
or prior to the Commencement Date, the Company shall take all necessary action, if any, and such actions as reasonably requested
by the Buyer, in order to render inapplicable any control share acquisition, business combination, stockholder rights plan or poison
pill (including any distribution under a rights agreement) or other similar anti-takeover provision under the Certificate of Incorporation
or the laws of the jurisdiction of its incorporation that is or could become applicable to the Buyer as a result of the transactions
contemplated by this Agreement, including, without limitation, the Company's issuance of the Securities and the Buyer's ownership
of the Securities; and

 

    	 	-14-	 

     

    

(o)       The
Company shall have provided the Buyer with the information reasonably requested by the Buyer in connection with its due diligence
requests made prior to, or in connection with, the Commencement, in accordance with the terms of Section 4(f) hereof.

 

		8.	INDEMNIFICATION. 

 

In consideration of the Buyer’s execution
and delivery of the Transaction Documents and acquiring the Securities hereunder and in addition to all of the Company’s
other obligations under the Transaction Documents, the Company shall defend, protect, indemnify and hold harmless the Buyer and
all of its affiliates, members, officers, directors, and employees, and any of the foregoing person’s agents or other representatives
(including, without limitation, those retained in connection with the transactions contemplated by this Agreement) (collectively,
the “Indemnitees”) from and against any and all third party actions, causes of action, suits, claims, losses,
costs, penalties, fees, liabilities and damages, and expenses in connection therewith (irrespective of whether any such Indemnitee
is a party to the action for which indemnification hereunder is sought), and including reasonable attorneys’ fees and disbursements
(the “Indemnified Liabilities”), incurred by any Indemnitee as a result of, or arising out of, or relating to
(a) any misrepresentation or breach of any representation or warranty made by the Company in the Transaction Documents or any other
certificate, instrument or document contemplated hereby or thereby, (b) any breach of any covenant, agreement or obligation of
the Company contained in the Transaction Documents or any other certificate, instrument or document contemplated hereby or thereby,
or (c) any cause of action, suit or claim brought or made against such Indemnitee and arising out of or resulting from the execution,
delivery, performance or enforcement of the Transaction Documents or any other certificate, instrument or document contemplated
hereby or thereby, other than with respect to Indemnified Liabilities which directly and primarily result from (A) a breach of
any of the Buyer’s representations and warranties, covenants or agreements contained in this Agreement, or (B) the gross
negligence, bad faith or willful misconduct of the Buyer or any other Indemnitee. To the extent that the foregoing undertaking
by the Company may be unenforceable for any reason, the Company shall make the maximum contribution to the payment and satisfaction
of each of the Indemnified Liabilities which is permissible under applicable law.

 

9.       EVENTS
OF DEFAULT. 

 

An “Event of Default” shall be
deemed to have occurred at any time as any of the following events occurs:

 

(a)       during
any period in which the effectiveness of any registration statement is required to be maintained pursuant to the terms of the Registration
Rights Agreement, the effectiveness of such registration statement lapses for any reason (including, without limitation, the issuance
of a stop order) or is unavailable to the Company for sale of all of the Registrable Securities (as defined in the Registration
Rights Agreement) to the Buyer in accordance with the terms of the Registration Rights Agreement, and such lapse or unavailability
continues for a period of ten (10) consecutive Business Days or for more than an aggregate of sixty (60) Business Days in any 365-day
period, which is not in connection with a post-effective amendment to any such registration statement or the filing of a new registration
statement; provided, however, that in connection with any post-effective amendment to such registration statement or filing of
a new registration statement that is required to be declared effective by the SEC, such lapse or unavailability may continue for
a period of no more than sixty (60) consecutive Business Days, which such period shall be extended for an additional thirty (30)
Business Days if the Company receives a comment letter from the SEC in connection therewith;

 

    	 	-15-	 

     

    

(b)       the
suspension from trading or failure of the Common Shares to be listed on the U.S. Exchange for a period of three (3) consecutive
Business Days;

 

(c)       the
delisting of the Common Shares from the Nasdaq Capital Market, if the Common Shares are not immediately thereafter trading on the
New York Stock Exchange, the NYSE American, the Nasdaq Global Select Market, or the Nasdaq Global Market;

 

(d)       the
failure for any reason by the Transfer Agent to issue Purchase Shares to the Buyer within five (5) Business Days after the applicable
payment has been made by the Buyer to the Company;

 

(e)       the
Company’s breach of any representation or warranty (as of the dates made), covenant or other term or condition under any
Transaction Document if such breach would reasonably be expected to have a Material Adverse Effect and except, in the case of a
breach of a covenant which is reasonably curable, only if such breach continues uncured for a period of at least five (5) Business
Days;

 

(f)       if
any Person commences a proceeding against the Company pursuant to or within the meaning of any Bankruptcy Law;

 

(g)       if
the Company pursuant to or within the meaning of any Bankruptcy Law; (A) commences a voluntary case, (B) consents to the entry
of an order for relief against it in an involuntary case, (C) consents to the appointment of a Custodian of it or for all or substantially
all of its property, (D) makes a general assignment for the benefit of its creditors or (E) becomes insolvent;

 

(h)       a court
of competent jurisdiction enters an order or decree under any Bankruptcy Law that (A) is for relief against the Company in an involuntary
case, (B) appoints a Custodian of the Company or for all or substantially all of its property, or (C) orders the liquidation of
the Company or any Subsidiary; or

 

(i)       if
at any time after the Commencement Date, the Exchange Cap is reached unless and until shareholder approval is obtained pursuant
to Section 1(h) hereof. The Exchange Cap shall be deemed to be reached at such time if, upon submission of a Purchase Notice or
VWAP Purchase Notice under this Agreement, the issuance of such number of Common Shares would exceed the number of Common Shares
which the Company may issue under this Agreement without breaching the Company’s obligations under the rules or regulations
of the Exchanges.

 

In addition to any other rights and remedies under applicable law and
this Agreement, including the Buyer termination rights under Section 11(k) hereof, so long as an Event of Default has occurred
and is continuing, or if any event which, after notice and/or lapse of time, would become an Event of Default, has occurred and
is continuing, or so long as the Closing Sale Price is below the Floor Price, the Company may not require and the Buyer shall not
be obligated to purchase any Common Shares under this Agreement. If pursuant to or within the meaning of any Bankruptcy Law, the
Company commences a voluntary case or any Person commences a proceeding against the Company, a Custodian is appointed for the Company
or for all or substantially all of its property, or the Company makes a general assignment for the benefit of its creditors, (any
of which would be an Event of Default as described in Sections 9(f), 9(g) and 9(h) hereof) this Agreement shall automatically terminate
without any liability or payment to the Company without further action or notice by any Person. No such termination of this Agreement
under Section 11(k)(i) shall affect the Company’s or the Buyer’s obligations under this Agreement with respect to pending
purchases and the Company and the Buyer shall complete their respective obligations with respect to any pending purchases under
this Agreement.

 

    	 	-16-	 

     

    

10.       CERTAIN
DEFINED TERMS. 

 

For purposes of this Agreement, the following terms
shall have the following meanings:

 

(a)       “1933
Act” means the Securities Act of 1933, as amended.

 

(b)       “Available
Amount” means initially Twenty Million Dollars ($20,000,000) in the aggregate which amount shall be reduced by the Purchase
Amount each time the Buyer purchases Common Shares pursuant to Section 1 hereof.

 

(c)       “Bankruptcy
Law” means Title 11, U.S. Code, or any similar Canadian, U.S. federal or state or foreign law for the relief of debtors.

 

(d)       “Business
Day” means any day on which the U.S. Exchange is open for trading during normal trading hours (i.e., 9:30 a.m. to 4:00
p.m. Eastern Time), including any day on which the U.S. Exchange is open for trading for a period of time less than the customary
time.

 

(e)       “Closing
Sale Price” means the last closing trade price for the Common Shares on the U.S. Exchange as reported by the U.S. Exchange.

 

(f)       “Confidential
Information” means any information disclosed by either party to the other party, either directly or indirectly, in writing,
orally or by inspection of tangible objects (including, without limitation, documents, prototypes, samples, plant and equipment),
which is designated as "Confidential," "Proprietary" or some similar designation. Information communicated
orally shall be considered Confidential Information if such information is expressly identified as Confidential Information at
the time of such initial disclosure and confirmed in writing as being Confidential Information within ten (10) Business Days after
the initial disclosure. Confidential Information may also include information disclosed to a disclosing party by third parties.
Confidential Information shall not, however, include any information which (i) was publicly known and made generally available
in the public domain prior to the time of disclosure by the disclosing party; (ii) becomes publicly known and made generally available
after disclosure by the disclosing party to the receiving party through no action or inaction of the receiving party; (iii) is
already in the possession of the receiving party at the time of disclosure by the disclosing party as shown by the receiving party’s
files and records immediately prior to the time of disclosure; (iv) is obtained by the receiving party from a third party without
a breach of such third party’s obligations of confidentiality; (v) is independently developed by the receiving party without
use of or reference to the disclosing party’s Confidential Information, as shown by documents and other competent evidence
in the receiving party’s possession; or (vi) is required by law to be disclosed by the receiving party, provided that the
receiving party gives the disclosing party prompt written notice of such requirement prior to such disclosure and assistance in
obtaining an order protecting the information from public disclosure.

 

    	 	-17-	 

     

    

(g)       “Custodian”
means any receiver, trustee, assignee, liquidator or similar official under any Bankruptcy Law.

 

(h)       “Exchanges”
means the U.S. Exchange and the TSX;

 

(i)       “Maturity
Date” means the date that is thirty (30) months from the Commencement Date.

 

(j)       “Person”
means an individual or entity including any limited liability company, a partnership, a joint venture, a corporation, a trust,
an unincorporated organization and a government or any department or agency thereof.

 

(k)       “Purchase
Amount” means, with respect to any particular purchase made hereunder, the portion of the Available Amount to be purchased
by the Buyer pursuant to Section 1 hereof as set forth in a valid Purchase Notice or VWAP Purchase Notice which the Company delivers
to the Buyer.

 

(l)       “Purchase
Date” means, with respect to any Regular Purchase made hereunder, the Business Day of receipt by the Buyer of a valid
Purchase Notice that the Buyer is to buy Purchase Shares pursuant to Section 1(b) hereof.

 

(m)        “Purchase
Notice” shall mean an irrevocable written notice from the Company to the Buyer directing the Buyer to buy Purchase Shares
pursuant to Section 1(b) hereof as specified by the Company therein at the applicable Purchase Price on the Purchase Date.

 

(n)        “Purchase
Price” means the lesser of (i) the lowest Sale Price of the Common Shares on the Purchase Date or (ii) the arithmetic
average of the three (3) lowest Closing Sale Prices for the Common Shares during the ten (10) consecutive Business Days ending
on the Business Day immediately preceding such Purchase Date (to be appropriately adjusted for any reorganization, recapitalization,
non-cash dividend, stock split, reverse stock split or other similar transaction).

 

(o)       “Sale
Price” means any trade price for the Common Shares on the U.S. Exchange during normal trading hours, as reported by the
U.S. Exchange.

 

(p)       “SEC”
means the United States Securities and Exchange Commission.

 

(q)       “Transfer
Agent” means the transfer agent of the Company as set forth in Section 11(f) hereof or such other person who is then
serving as the transfer agent for the Company in respect of the Common Shares.

 

(r)       “TSX”
means the Toronto Stock Exchange.

 

(s)        “U.S.
Exchange” means the NASDAQ Capital Market; provided however, that in the event the Company’s Common Shares are
ever listed or traded on the New York Stock Exchange, the NYSE MKT, the Nasdaq Global Select Market, the Nasdaq Global Market,
the OTC Bulletin Board or either of the OTCQB marketplace or the OTCQX marketplace of the OTC Markets Group, then the “U.S.
Exchange” shall mean such other market or exchange on which the Company’s Common Shares are then listed or traded.

 

    	 	-18-	 

     

    

(t)       “VWAP
Minimum Price Threshold” means, with respect to any particular VWAP Purchase Notice, the Sale Price on the VWAP Purchase
Date equal to the greater of (i) 80% of the Closing Sale Price on the Business Day immediately preceding the VWAP Purchase Date
or (ii) such higher price as set forth by the Company in the VWAP Purchase Notice.

 

(u)       “VWAP
Purchase Amount” means, with respect to any particular VWAP Purchase Notice, the portion of the Available Amount to be
purchased by the Buyer pursuant to Section 1(c) hereof pursuant to a valid VWAP Purchase Notice which requires the Buyer to buy
the VWAP Purchase Share Percentage of the aggregate shares traded on the U.S. Exchange during normal trading hours on the VWAP
Purchase Date up to the VWAP Purchase Share Volume Maximum, subject to the VWAP Minimum Price Threshold.

 

(v)       “VWAP
Purchase Date” means, with respect to any VWAP Purchase made hereunder, the Business Day following the receipt by the
Buyer of a valid VWAP Purchase Notice that the Buyer is to buy Purchase Shares pursuant to Section 1(c) hereof.

 

(w)       “VWAP
Purchase Notice” shall mean an irrevocable written notice from the Company to the Buyer directing the Buyer to buy Purchase
Shares on the VWAP Purchase Date pursuant to Section 1(c) hereof as specified by the Company therein at the applicable VWAP Purchase
Price with the applicable VWAP Purchase Share Percentage specified therein.

 

(x)       “VWAP
Purchase Share Percentage” means, with respect to any particular VWAP Purchase Notice pursuant to Section 1(c) hereof,
the percentage set forth in the VWAP Purchase Notice which the Buyer will be required to buy as a specified percentage of the aggregate
shares traded on the U.S. Exchange during normal trading hours up to the VWAP Purchase Share Volume Maximum on the VWAP Purchase
Date subject to Section 1(c) hereof but in no event shall this percentage exceed thirty percent (30%) of such VWAP Purchase Date’s
share trading volume of the Common Shares on the U.S. Exchange during normal trading hours.

 

(y)        “VWAP
Purchase Price” means the lesser of (i) the Closing Sale Price on the VWAP Purchase Date; or (ii) ninety-seven percent
(97%) of volume weighted average price for the Common Shares traded on the U.S. Exchange during normal trading hours on (A) the
VWAP Purchase Date if the aggregate shares traded on the U.S. Exchange on the VWAP Purchase Date have not exceeded the VWAP Purchase
Share Volume Maximum and the Sale Price of Common Shares has not fallen below the VWAP Minimum Price Threshold (to be appropriately
adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction),
or (B) the portion of the VWAP Purchase Date until such time as the sooner to occur of (1) the time at which the aggregate shares
traded on the U.S. Exchange has exceeded the VWAP Purchase Share Volume Maximum, or (2) the time at which the Sale Price of Common
Shares falls below the VWAP Minimum Price Threshold (to be appropriately adjusted for any reorganization, recapitalization, non-cash
dividend, stock split, reverse stock split or other similar transaction).

 

(z)        “VWAP
Purchase Share Estimate” means the number of shares of Common Shares that the Company has in its sole discretion estimated
in connection with a VWAP Purchase Notice pursuant to Section 1(c) hereof (to be appropriately adjusted for any reorganization,
recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction).

 

    	 	-19-	 

     

    

(aa) “VWAP Purchase Share Volume Maximum”
means a number of shares of Common Shares traded on the U.S. Exchange during normal trading hours on the VWAP Purchase Date equal
to: (i) the VWAP Purchase Share Estimate, divided by (ii) the VWAP Purchase Share Percentage (to be appropriately adjusted for
any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction).

 

11.       MISCELLANEOUS.

 

(a)       Governing
Law; Jurisdiction; Jury Trial. The laws of the Province of Ontario shall governall issues concerning the relative rights of
the Company and its shareholders. All other questions concerning the construction, validity, enforcement and interpretation of
this Agreement and the other Transaction Documents shall be governed by the internal laws of the State of Illinois, without giving
effect to any choice of law or conflict of law provision or rule (whether of the State of Illinois or any other jurisdictions)
that would cause the application of the laws of any jurisdictions other than the State of Illinois. Each party hereby irrevocably
submits to the exclusive jurisdiction of the state and federal courts sitting in the City of Chicago, for the adjudication of any
dispute hereunder or under the other Transaction Documents or in connection herewith or therewith, or with any transaction contemplated
hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim
that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an
inconvenient forum or that the venue of such suit, action or proceeding is improper. Each party hereby irrevocably waives personal
service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such
party at the address for such notices to it under this Agreement and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process
in any manner permitted by law. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY
TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION
CONTEMPLATED HEREBY.

 

(b)       Counterparts.
This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile
or pdf (or other electronic reproduction) signature shall be considered due execution and shall be binding upon the signatory thereto
with the same force and effect as if the signature were an original, not a facsimile or pdf (or other electronic reproduction)
signature.

 

(c)       Headings.
The headings of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this
Agreement.

 

(d)       Severability.
If any provision of this Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall
not affect the validity or enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability
of any provision of this Agreement in any other jurisdiction.

 

    	 	-20-	 

     

    

(e)       Entire
Agreement. This Agreement and the Registration Rights Agreement supersede all other prior oral or written agreements between
the Buyer, the Company, their affiliates and persons acting on their behalf with respect to the matters discussed herein, and this
Agreement, the other Transaction Documents and the instruments referenced herein contain the entire understanding of the parties
with respect to the matters covered herein and therein and, except as specifically set forth herein or therein, neither the Company
nor the Buyer makes any representation, warranty, covenant or undertaking with respect to such matters. Each of the Company and
the Buyer acknowledges and agrees that it has not relied on, in any manner whatsoever, any representations or statements, written
or oral, other than as expressly set forth in this Agreement. The Buyer and the Company agree the Common Share Purchase Agreement,
dated as of May 30, 2018, by and between the Company and the Buyer, is hereby terminated in accordance with its terms.

 

(f)       Notices.
Any notices, consents or other communications required or permitted to be given under the terms of this Agreement must be in writing
and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon receipt, when sent by facsimile
(provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending party); (iii)
upon receipt, when sent by electronic message (provided the recipient responds to the message and confirmation of both electronic
messages are kept on file by the sending party); or (iv) one (1) Business Day after timely deposit with a nationally recognized
overnight delivery service, in each case properly addressed to the party to receive the same. The addresses and facsimile numbers
for such communications shall be:

 

If to the Company:

 

Aptose Biosciences Inc.

251 Consumers Road, Suite 1105

Toronto, Ontario M2J 4R3

Telephone:650-718-5028

Facsimile:905-234-2120

Attention: Gregory K. Chow, CFO

Email: gchow@aptose.com

 

With a copy (which shall not constitute notice)
to:

 

Dorsey & Whitney LLP

Suite 1070 – 1095 West Pender Street

Vancouver, B.C. V6E 2M6

Canada

Telephone: 604-630-5199

Facsimile: 604-687-8504

Attention: Daniel M. Miller

Email: miller.dan@dorsey.com

 

If to the Buyer:

 

Aspire Capital Fund, LLC

155 North Wacker Drive, Suite 1600

Chicago, IL 60606

Telephone:312-658-0400

Facsimile:312-658-4005

Attention:Steven G. Martin

Email:smartin@aspirecapital.com

 

    	 	-21-	 

     

    

With a copy to (which shall not constitute delivery
to the Buyer):

 

Morrison & Foerster LLP

2000 Pennsylvania Avenue, NW, Suite 6000

Washington, DC 20006

Telephone:202-778-1611

Facsimile:202-887-0763

Attention:Martin P. Dunn, Esq.

Email:       mdunn@mofo.com

 

If to the Transfer Agent:

 

Computershare Investor Services Inc.

100 University Avenue, 8th Floor

Toronto, ON M5J 2Y1

Telephone: 416-263-9534

Facsimile: 888-453-0330

Attention: Paul Allen

Email: paul.allen@computershare.com

 

or at such other address and/or facsimile number and/or to the attention
of such other person as the recipient party has specified by written notice given to each other party at least one (1) Business
Day prior to the effectiveness of such change. Written confirmation of receipt (A) given by the recipient of such notice, consent
or other communication, (B) mechanically or electronically generated by the sender’s facsimile machine containing the time,
date, and recipient facsimile number, (C) electronically generated by the sender’s electronic mail containing the time, date
and recipient email address or (D) provided by a nationally recognized overnight delivery service, shall be rebuttable evidence
of receipt in accordance with clause (i), (ii), (iii) or (iv) above, respectively.

 

(g)       Successors
and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors and
assigns. The Company shall not assign this Agreement or any rights or obligations hereunder without the prior written consent of
the Buyer, including by merger or consolidation; provided, however, that any transaction, whether by merger, reorganization, restructuring,
consolidation, financing or otherwise, whereby the Company remains the surviving entity immediately after such transaction shall
not be deemed a succession or assignment. The Buyer may not assign its rights or obligations under this Agreement.

 

(h)       No
Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted
successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other person.

 

(i)       Publicity.
The Buyer shall have the right to approve before issuance any press release, SEC filing or any other public disclosure made by
or on behalf of the Company whatsoever with respect to, in any manner, the Buyer, its purchases hereunder or any aspect of this
Agreement or the transactions contemplated hereby; provided, however, that the Company shall be entitled, without the prior approval
of the Buyer, to make any press release or other public disclosure (including any filings with the SEC or with Canadian securities
regulatory authorities) with respect to such transactions as is required by applicable law and regulations so long as the Company
and its counsel consult with the Buyer in connection with any such press release or other public disclosure at least one (1) Business
Day prior to its release; provided, however, that the Company’s obligations pursuant to this Section 11(i) shall not apply
if the material provisions of such press release, SEC filing, or other public disclosure previously has been publicly disclosed
by the Company in accordance with this Section 11(i). The Buyer must be provided with a copy thereof at least one (1) Business
Day prior to any release or use by the Company thereof.

 

    	 	-22-	 

     

    

(j)       Further
Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall
execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request
in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated
hereby.

 

(k)       Termination.
This Agreement may be terminated only as follows:

 

(i)       By
the Buyer any time an Event of Default exists without any liability or payment to the Company. However, if pursuant to or within
the meaning of any Bankruptcy Law, the Company commences a voluntary case or any Person commences a proceeding against the Company,
a Custodian is appointed for the Company or for all or substantially all of its property, or the Company makes a general assignment
for the benefit of its creditors, (any of which would be an Event of Default as described in Sections 9(f), 9(g) and 9(h) hereof)
this Agreement shall automatically terminate without any liability or payment to the Company without further action or notice by
any Person. No such termination of this Agreement under this Section 11(k)(i) shall affect the Company’s or the Buyer’s
obligations under this Agreement with respect to pending purchases and the Company and the Buyer shall complete their respective
obligations with respect to any pending purchases under this Agreement.

 

(ii)       In
the event that the Commencement shall not have occurred the Company shall have the option to terminate this Agreement for any reason
or for no reason without any liability whatsoever of either party to the other party under this Agreement.

 

(iii)       In
the event that the Commencement shall not have occurred within ten (10) Business Days of the date of this Agreement, due to the
failure to satisfy any of the conditions set forth in Sections 6 and 7 above with respect to the Commencement, either party shall
have the option to terminate this Agreement at the close of business on such date or thereafter without liability of either party
to any other party; provided, however, that the right to terminate this Agreement under this Section 11(k)(iii) shall not be available
to either party if such failure to satisfy any of the conditions set forth in Sections 6 and 7 is the result of a breach of this
Agreement by such party or the failure of any representation or warranty of such party included in this Agreement to be true and
correct in all material respects.

 

(iv)       
At any time after the Commencement Date, the Company shall have the option to terminate this Agreement for any reason or for no
reason by delivering notice (a “Company Termination Notice”) to the Buyer electing to terminate this Agreement
without any liability whatsoever of either party to the other party under this Agreement. The Company Termination Notice shall
not be effective until one (1) Business Day after it has been received by the Buyer.

 

    	 	-23-	 

     

    

(v)       This
Agreement shall automatically terminate on the date that the Company sells and the Buyer purchases the full Available Amount as
provided herein, without any action or notice on the part of any party and without any liability whatsoever of any party to any
other party under this Agreement.

 

(vi)       If
by the Maturity Date for any reason or for no reason the full Available Amount under this Agreement has not been purchased as provided
for in Section 1 of this Agreement, this Agreement shall automatically terminate on the Maturity Date, without any action or notice
on the part of any party and without any liability whatsoever of any party to any other party under this Agreement.

 

Except as set forth in Sections 11(k)(i) (in respect of an
Event of Default under Sections 9(f), 9(g) and 9(h)), 11(k)(v) and 11(k)(vi), any termination of this Agreement pursuant to this
Section 11(k) shall be effected by written notice from the Company to the Buyer, or the Buyer to the Company, as the case may be,
setting forth the basis for the termination hereof. The representations and warranties of the Company and the Buyer contained in
Sections 2, 3 and 5 hereof, the indemnification provisions set forth in Section 8 hereof and the agreements and covenants set forth
in Sections 4(e) and 11, shall survive the Commencement and any termination of this Agreement. No termination of this Agreement
shall affect the Company’s or the Buyer’s rights or obligations (i) under the Registration Rights Agreement which shall
survive any such termination in accordance with its terms or (ii) under this Agreement with respect to pending purchases and the
Company and the Buyer shall complete their respective obligations with respect to any pending purchases under this Agreement.

 

(l)       No
Financial Advisor, Placement Agent, Broker or Finder. The Company represents and warrants to the Buyer that it has not engaged
any financial advisor, placement agent, broker or finder in connection with the transactions contemplated hereby. The Buyer represents
and warrants to the Company that it has not engaged any financial advisor, placement agent, broker or finder in connection with
the transactions contemplated hereby. Each party shall be responsible for the payment of any fees or commissions, if any, of any
financial advisor, placement agent, broker or finder engaged by such party relating to or arising out of the transactions contemplated
hereby. Each party shall pay, and hold the other party harmless against, any liability, loss or expense (including, without limitation,
attorneys' fees and out of pocket expenses) arising in connection with any such claim.

 

(m)       No
Strict Construction. The language used in this Agreement will be deemed to be the language chosen by the parties to express
their mutual intent, and no rules of strict construction will be applied against any party.

 

(n)       Failure
or Indulgence Not Waiver. No failure or delay in the exercise of any power, right or privilege hereunder shall operate as a
waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or further exercise
thereof or of any other right, power or privilege.

 

 

 * * * * *

 

    	 	-24-	 

     

    

IN WITNESS WHEREOF, the Buyer and the Company have caused this
Common Share Purchase Agreement to be duly executed as of the date first written above.

 

 

 

THE COMPANY:

 

APTOSE BIOSCIENCES INC.

 

By:______________________

Name: Gregory K. Chow

Title: Chief Financial Officer

 

 

BUYER:

 

ASPIRE CAPITAL FUND, LLC

BY: ASPIRE CAPITAL PARTNERS, LLC

BY: SGM
Holdings Corp.

 

By:_______________________

Name: Steven G. Martin

Title: President

 

 

 

 

 

    	 	-25-	 

     

    

Execution Copy

SCHEDULES

 

	Schedule 3(a)	Subsidiaries
	Schedule 3(c)	Capitalization
	Schedule 3(e)	Conflicts
	Schedule 3(f)	1934 Act Filings
	Schedule 3(g)	Material Changes
	Schedule 3(h)	Litigation
	Schedule 3(j)	Intellectual Property
	Schedule 3(l)	Title
	Schedule 3(p)	Transactions with Affiliates

 

EXHIBITS

 

	Exhibit A	Form of Officer’s Certificate
	Exhibit B	Form of Resolutions of Board of Directors of the Company
	Exhibit C	Form of Secretary’s Certificate

 

 

 

 

 

     

     

    

DISCLOSURE SCHEDULES

 

 

Schedule 3(a) – Subsidiaries

 

None.

 

Schedule 3(c) – Capitalization

 

None.

 

Schedule 3(e) – Conflicts

 

None.

 

Schedule 3(f) – 1934 Act Filings

 

None.

 

Schedule 3(g) – Material Changes

 

None.

 

Schedule 3(h) – Litigation

 

None.

 

Schedule 3(j) – Intellectual Property

 

None.

 

Schedule 3(l) – Title

 

None.

 

Schedule 3(p) – Transactions with Affiliates

 

None.

 

 

     

     

    

EXHIBIT A

 

FORM OF OFFICER’S CERTIFICATE

 

This Officer’s Certificate (“Certificate”)
is being delivered pursuant to Section 7(e) of that certain Common Share Purchase Agreement dated as of May 7, 2019 (the “Common
Share Purchase Agreement”), by and between APTOSE BIOSCIENCES INC., a corporation organized under the laws of
Canada (the “Company”), and ASPIRE CAPITAL FUND, LLC, an Illinois limited liability company (the “Buyer”).
Terms used herein and not otherwise defined shall have the meanings ascribed to them in the Common Share Purchase Agreement.

 

The undersigned, ___________, ____________ of the
Company, hereby certifies as follows:

 

1.       I
am the ______________ of the Company and make the statements contained in this Certificate in my capacity as such;

 

2.       The
representations and warranties of the Company are true and correct in all material respects (except to the extent that any of such
representations and warranties is already qualified as to materiality in Section 3 of the Common Share Purchase Agreement, in which
case, such representations and warranties are true and correct without further qualification) as of the date when made and as of
the Commencement Date as though made at that time (except for representations and warranties that speak as of a specific date);

 

3.       The
Company has performed, satisfied and complied in all material respects with covenants, agreements and conditions required by the
Transaction Documents to be performed, satisfied or complied with by the Company at or prior to the Commencement Date.

 

4.        The
Company has not taken any steps, and does not currently expect to take any steps, to seek protection pursuant to any Bankruptcy
Law nor does the Company or any of its Subsidiaries have any knowledge or reason to believe that its creditors intend to initiate
involuntary bankruptcy or insolvency proceedings. The Company is financially solvent and is generally able to pay its debts as
they become due.

  

IN WITNESS WHEREOF, I have hereunder signed my name
on this ___ day of ___________.

 

______________________

Name:

Title:

 

The undersigned as Secretary of Aptose Biosciences
Inc., a corporation organized under the laws of Canada, hereby certifies that ___________ is the duly elected, appointed, qualified
and acting ________ of APTOSE BIOSCIENCES INC. and that the signature appearing above is his/her genuine signature.

 

___________________________________

Secretary

     

     

    

EXHIBIT B

 

FORM OF COMPANY RESOLUTIONS

FOR SIGNING PURCHASE AGREEMENT

 

WHEREAS, management has reviewed with the Board
of Directors the background, terms and conditions of the transactions subject to the proposed Common Share Purchase Agreement (the “Purchase
Agreement”) by and between the Company and Aspire Capital Fund, LLC (“Aspire Capital”), including
all materials terms and conditions of the transactions subject thereto, providing for the purchase by Aspire Capital of up to Twenty
Million Dollars ($20,000,000) of the Company’s common shares, without par value (the “Common Shares”);

WHEREAS, after careful consideration of the
Purchase Agreement, the documents incident thereto and other factors deemed relevant by the Board of Directors, the Board of Directors
has determined that it is advisable and in the best interests of the Company to engage in the transactions contemplated by the
Purchase Agreement (the “Offering”), including, but not limited to, the issuance of $360,000 of Common
Shares to Aspire Capital at a price per share based on the five-day volume weighted average trading price of the Common Shares
on the NASDAQ Capital Market (“NASDAQ”) during the 5 days prior to the execution of the Purchase Agreement as
a commitment fee (the “Commitment Shares”) and the sale of additional Common Shares to Aspire Capital up
to the available amount under the Purchase Agreement (the “Purchase Shares”, and together with the Commitment
Shares, the “Aspire Shares”);

WHEREAS on March 12, 2019, the Company filed
a base shelf prospectus (the “Shelf Prospectus”) with the United States Securities and Exchange Commission
(the “SEC”) for the offering of up to US$100,000,000 Common Shares, warrants or units of the Company, and such
registration statement was declared effective by the SEC on April 25, 2019 (the “Registration Statement”);

WHEREAS the Company intends to file with
the SEC a prospectus supplement (the “Prospectus Supplement”) to the Shelf Prospectus qualifying the offer
and sale of Common Shares having an aggregate offering price of up to US$20,360,000 (including the Commitment Shares), a draft
of which has been provided to the board of directors of the Company (the “Board”);

WHEREAS the Company will be required to execute
and deliver certain agreements and documents to complete the transactions contemplated hereby;

WHEREAS the Company proposes to list the
Common Shares on the Toronto Stock Exchange and the NASDAQ Capital Market;

 

Transaction Documents

IT IS RESOLVED, that the Company be and it
hereby is authorized to execute the Purchase Agreement providing for the purchase of common shares of the Company having an aggregate
value of up to $20,000,000 and the issuance of the Commitment Shares having an aggregate value of $360,000;

IT IS RESOLVED, that the terms and provisions
of the Form of Transfer Agent Instructions (the “Instructions”) are hereby approved and the President and
Chief Executive Officer and the Senior Vice President and Chief Financial Officer (the “Authorized Officers”)
are authorized to execute and deliver the Instructions (pursuant to the terms of the Purchase Agreement), with such amendments,
changes, additions and deletions as the Authorized Officers may deem appropriate and approve on behalf of, the Company, such approval
to be conclusively evidenced by the signature of an Authorized Officer thereon;

     

     

    

Issuance of Common Shares

IT IS RESOLVED, that the Company is hereby
authorized to issue the Commitment Shares to Aspire Capital and that upon issuance of the Commitment Shares pursuant to the Purchase
Agreement, the Commitment Shares shall be duly authorized, validly issued, fully paid and non-assessable;

IT IS RESOLVED, that the Company is hereby
authorized to issue Common Shares upon the purchase of Purchase Shares up to the available amount under the Purchase Agreement
in accordance with the terms of the Purchase Agreement and that, upon issuance of the Purchase Shares pursuant to the Purchase
Agreement, the Purchase Shares will be duly authorized, validly issued, fully paid and non-assessable;

Listing of Shares on the Exchanges

IT IS RESOLVED, that the officers of the Company
with the assistance of counsel be, and each of them hereby is, authorized and directed to take all necessary steps and do all other
things necessary and appropriate to effect the listing of the Aspire Shares on the NASDAQ and the Toronto Stock Exchange;

 

Prospectus Supplement 

IT IS RESOLVED to authorize and approve the Prospectus
Supplement, substantially in the forms provided to the Board, subject to such amendments, changes, additions and deletions as any
director or officer of the Company may approve;

 

IT IS RESOLVED to authorize any director or officer
of the Company to file or cause to be filed the Prospectus Supplement with the SEC and to file all such other documents and supporting
material and to execute and deliver all such documents and instruments and to do all such other acts and things as in the opinion
of any such director or officer may be necessary or desirable to give full effect to this resolution;

 

Press Release

IT IS RESOLVED to authorize the Company to issue,
when appropriate, a press release announcing the Offering (the “Press Release”);

 

IT IS RESOLVED to authorize any officer or director
to approve the Press Release;

 

General

IT IS RESOLVED, that, without limiting the foregoing,
the Authorized Officers are, and each of them hereby is, authorized and directed to proceed on behalf of the Company and to take
all such steps as deemed necessary or appropriate, with the advice and assistance of counsel, to cause the Company to consummate
the agreements referred to herein and to perform its obligations under such agreements; and

 

     

     

    

IT IS RESOLVED, that the Authorized Officers be,
and each of them hereby is, authorized, empowered and directed on behalf of and in the name of the Company, to take or cause to
be taken all such further actions and to execute and deliver or cause to be executed and delivered all such further agreements,
amendments, documents, certificates, reports, schedules, applications, notices, letters and undertakings and to incur and pay all
such fees and expenses as in their judgment shall be necessary, proper or desirable to carry into effect the purpose and intent
of any and all of the foregoing resolutions, and that all actions heretofore taken by any officer or director of the Company in
connection with the transactions contemplated by the agreements described herein are hereby approved, ratified and confirmed in
all respects;

 

IT IS RESOLVED, that any and all actions heretofore
or hereinafter taken on behalf of the Company by any of said persons or entities within the terms of the foregoing resolutions
are hereby approved, ratified and confirmed in all respects as the acts and deeds of the Company; and

 

IT IS RESOLVED to approve and ratify any and all
acts of any nature previously performed by the directors and officers of the Company in connection with the Offering.

 

 

 

     

     

    

EXHIBIT C

 

FORM OF SECRETARY’S CERTIFICATE

 

This Secretary’s Certificate (the “Certificate”)
is being delivered pursuant to Section 7(k) of that certain Common Share Purchase Agreement dated as of May 7, 2019 (the “Common
Share Purchase Agreement”), by and between APTOSE BIOSCIENCES INC., a corporation organized under the laws of
Canada (the “Company”) and ASPIRE CAPITAL FUND, LLC, an Illinois limited liability company (the “Buyer”),
pursuant to which the Company may sell to the Buyer up to Twenty Million Dollars ($20,000,000) of the Company’s common shares
without par value (the “Common Shares”). Terms used herein and not otherwise defined shall have the meanings
ascribed to them in the Common Share Purchase Agreement.

 

The undersigned, _________________ Secretary of the Company, hereby certifies
as follows in his capacity as such:

 

1.       I
am the Secretary of the Company and make the statements contained in this Secretary’s Certificate.

 

2.       Attached
hereto as Exhibit A and Exhibit B are true, correct and complete copies of the Company’s bylaws (“Bylaws”)
and Certificate of Incorporation (“Certificate of Incorporation”), respectively, in each case, as amended through
the date hereof, and no action has been taken by the Company, its directors, officers or shareholders, in contemplation of the
filing of any further amendment relating to or affecting the Bylaws or Articles.

 

3.       Attached
hereto as Exhibit C are true, correct and complete copies of the resolutions duly adopted by the Board of Directors of the Company
on ____________, 201__. Such resolutions have not been amended, modified or rescinded and remain in full force and effect and such
resolutions are the only resolutions adopted by the Company’s Board of Directors, or any committee thereof, or the shareholders
of the Company relating to or affecting (i) the entering into and performance of the Common Share Purchase Agreement, or the issuance,
offering and sale of the Purchase Shares and the Commitment Shares and (ii) and the performance of the Company of its obligation
under the Transaction Documents as contemplated therein.

 

4.       As of
the date hereof, the authorized, issued and reserved capital of the Company is as set forth on Exhibit D hereto.

 

IN WITNESS WHEREOF, I have hereunder signed
my name on this ___ day of ____________.

 

_________________________

_________________, Secretary

 

The undersigned as ______________ of APTOSE BIOSCIENCES INC.,
a corporation organized under the laws of Canada, hereby certifies that _______________ is the duly elected, appointed, qualified
and acting Secretary of APTOSE BIOSCIENCES INC., and that the signature appearing above is his/her genuine signature.

 

_______________________________

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00295-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00295-of-00352.parquet"}]]